aimd_10q.htm

0001654954-23-010601.txt : 20230811 0001654954-23-010601.hdr.sgml : 20230811 20230811161501 ACCESSION NUMBER: 0001654954-23-010601 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 56 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230811 DATE AS OF CHANGE: 20230811 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ainos, Inc. CENTRAL INDEX KEY: 0001014763 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 751974352 STATE OF INCORPORATION: TX FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-41461 FILM NUMBER: 231164279 BUSINESS ADDRESS: STREET 1: AINOS, INC. STREET 2: 8880 RIO SAN DIEGO DRIVE SUITE 800 CITY: SAN DIEGO STATE: CA ZIP: 92108 BUSINESS PHONE: 858-869-2986 MAIL ADDRESS: STREET 1: AINOS, INC. STREET 2: 8880 RIO SAN DIEGO DRIVE SUITE 800 CITY: SAN DIEGO STATE: CA ZIP: 92108 FORMER COMPANY: FORMER CONFORMED NAME: AMARILLO BIOSCIENCES INC DATE OF NAME CHANGE: 19960516 10-Q 1 aimd_10q.htm FORM 10-Q aimd_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2023

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from____to____

Commission File No. 0-20791

AINOS, INC.

(Exact name of registrant as specified in its charter)

Texas

75-1974352

(State or other jurisdiction

of incorporation or organization)

(IRS Employer

Identification No.)

8880 Rio San Diego Drive, Ste. 800, San Diego, CA 92108

(858) 869-2986

(Address and telephone number, including area code, of registrant's principal executive offices)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	AIMD	The Nasdaq Stock Market LLC
Warrants to purchase Common Stock	AIMDW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated Filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) ☐ Yes ☒ No

20,292,624 shares of common stock, par value $0.01 per share, outstanding as of August 11, 2023

AINOS, INC.

INDEX

		PAGE NO.
PART I:	FINANCIAL INFORMATION
ITEM 1.	Financial Statements	3
	Condensed Balance Sheets– June 30, 2023 and December 31, 2022 (unaudited)	3
	Condensed Statements of Operations – Three and Six Months Ended June 30, 2023 and 2022 (unaudited)	4
	Condensed Statements of Comprehensive Loss – Three and Six Months Ended June 30, 2023 and 2022 (unaudited)	5
	Condensed Statements of Stockholders’ Equity– Three Months Ended June 30, 2023 and 2022 (unaudited)	6
	Condensed Statements of Stockholders’ Equity– Six Months Ended June 30, 2023 and 2022 (unaudited)	7
	Condensed Statements of Cash Flows – Six Months Ended June 30, 2023 and 2022 (unaudited)	8
	Notes to Condensed Financial Statements (unaudited)	9
ITEM 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	17
ITEM 3.	Quantitative and Qualitative Disclosures About Market Risk	22
ITEM 4.	Controls and Procedures	23

PART II:	OTHER INFORMATION
ITEM 1.	Legal Proceedings	24
ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	24
ITEM 3.	Defaults Upon Senior Securities	25
ITEM 4.	Mine Safety Disclosures	25
ITEM 5.	Other Information	25
ITEM 6.	Exhibits	26
Signatures		27

Table of Contents

PART I - FINANCIAL INFORMATION

ITEM 1. Financial Statements

Ainos, Inc.

Condensed Balance Sheets

(Unaudited)

	June 30,			December 31,
	2023			2022
Assets
Current assets:
Cash and cash equivalents	$	1,360,970		$	1,853,362
Accounts receivable (including amounts of related party of nil and $177,595 as of June 30, 2023 and December 31,2022, respectively)		9,385			201,546
Inventory, net		528,114			595,222
Other current assets		241,230			195,787
Total current assets		2,139,699			2,845,917
Intangible assets, net		30,564,203			32,806,738
Property and equipment, net		1,269,331			1,375,676
Other assets		73,169			80,683
Total assets	$	34,046,402		$	37,109,014

Liabilities and Stockholders' Equity
Current liabilities:
Convertible notes payable, related party	$	-		$	376,526
Other notes payable, related party		684,000			884,000
Accrued expenses and others current liabilities		429,503			1,212,386
Total current liabilities		1,113,503			2,472,912
Convertible notes payable (including amounts of related party of $1,500,000 and nil as of June 30, 2023 and December 31, 2022, respectively)		2,500,000			-
Other long-term liabilities		37,562			8,096
Total liabilities		3,651,065			2,481,008
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.01 par value; 10,000,000 shares authorized; none issued
Common stock, $0.01 par value; 300,000,000 shares authorized as of June 30, 2023 and December 31, 2022, 20,292,624 and 20,011,602 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively		202,926			200,116
Additional paid-in capital		59,423,678			58,745,149
Accumulated deficit		(28,985,808	)		(24,115,606	)
Translation adjustment		(245,459	)		(201,653	)
Total stockholders’ equity		30,395,337			34,628,006
Total liabilities and stockholders’ equity	$	34,046,402		$	37,109,014

See accompanying notes to condensed financial statements.

Table of Contents

Ainos, Inc.

Condensed Statements of Operations

(Unaudited)

	Three months ended June 30,						Six months ended June 30,
	2023			2022			2023			2022

Revenues	$	28,555		$	636,627		$	77,719		$	723,828
Cost of revenues		(55,817	)		(318,963	)		(156,665	)		(360,042	)
Gross (loss) profit		(27,262	)		317,664			(78,946	)		363,786
Operating expenses:
Research and development expenses		1,671,187			1,634,856			3,370,070			3,212,310
Selling, general and administrative expenses		618,149			627,104			1,380,614			1,178,834
Total operating expenses		2,289,336			2,261,960			4,750,684			4,391,144
Loss from operations		(2,316,598	)		(1,944,296	)		(4,829,630	)		(4,027,358	)

Non-operating income (expenses), net:
Interest expense		(40,311	)		(18,796	)		(49,585	)		(35,483	)
Other income, net		7,182			9,060			9,013			8,914
Total non-operating expenses, net		(33,129	)		(9,736	)		(40,572	)		(26,569	)

Net loss before income taxes		(2,349,727	)		(1,954,032	)		(4,870,202	)		(4,053,927	)
Provision for income taxes		-			-			-			-
Net loss	$	(2,349,727	)	$	(1,954,032	)	$	(4,870,202	)	$	(4,053,927	)

Net loss per common share - basic and diluted	$	(0.12	)	$	(0.20	)	$	(0.24	)	$	(0.42	)

Weighted-average shares used in computing net loss per common share-basic and diluted		20,095,705			9,625,133			20,053,886			9,625,133

See accompanying notes to condensed financial statements.

Table of Contents

Ainos, Inc.

Condensed Statements of Comprehensive Loss

(Unaudited)

	Three months ended June 30,						Six months ended June 30,
	2023			2022			2023			2022

Net loss	$	(2,349,727	)	$	(1,954,032	)	$	(4,870,202	)	$	(4,053,927	)
Other comprehensive loss:
Translation adjustment		(53,867	)		(165,687	)		(43,806	)		(223,746	)
Comprehensive loss	$	(2,403,594	)	$	(2,119,719	)	$	(4,914,008	)	$	(4,277,673	)

See accompanying notes to condensed financial statements.

Table of Contents

Ainos, Inc.

Condensed Statements of Stockholders’ Equity

For the three months ended June 30, 2023 and 2022 (Unaudited)

	Preferred Stock				Common Stock				Additional Paid-in						Accumulated Other Comprehensive			Total Stockholders’
	Shares		Amount		Shares		Amount		Capital			Deficit			Loss			Equity

Balance at March 31, 2023		-	$	-		20,011,602	$	200,116	$	58,965,981		$	(26,636,081	)	$	(191,592	)	$	32,338,424
Issuance of stock in exchange of vehicle		-		-		61,157		612		47,947			-			-			48,559
Conversion of convertible notes payable to common stock		-		-		93,333		933		273,856			-			-			274,789
Issuance of stock to settle vested RSUs		-		-		126,532		1,265		(1,265	)		-			-			-
Share-based compensation		-		-		-		-		137,159			-			-			137,159
Net loss		-		-		-		-		-			(2,349,727	)		-			(2,349,727	)
Translation adjustment		-		-		-		-		-			-			(53,867	)		(53,867	)
Balance at June 30, 2023		-	$	-		20,292,624	$	202,926	$	59,423,678		$	(28,985,808	)	$	(245,459	)	$	30,395,337

Balance at March 31, 2022		-	$	-		9,625,133	$	96,251	$	20,247,415		$	(12,208,811	)	$	(52,259	)	$	8,082,596
Share-based compensation		-		-		-		-		43,443			-			-			43,443
Net loss		-		-		-		-		-			(1,954,032	)		-			(1,954,032	)
Translation adjustment		-		-		-		-		-			-			(165,687	)		(165,687	)
Balance at June 30, 2022		-	$	-		9,625,133	$	96,251	$	20,290,858		$	(14,162,843	)	$	(217,946	)	$	6,006,320

See accompanying notes to condensed financial statements.

Table of Contents

Ainos, Inc.

Condensed Statements of Stockholders’ Equity

For the six months ended June 30, 2023 and 2022 (Unaudited)

	Preferred Stock				Common Stock				Additional Paid-in			Accumulated			Accumulated Other Comprehensive			Total Stockholders’
	Shares		Amount		Shares		Amount		Capital			Deficit			Loss			Equity

Balance at December 31, 2022		-	$	-		20,011,602	$	200,116	$	58,745,149		$	(24,115,606	)	$	(201,653	)	$	34,628,006
Issuance of stock in exchange of vehicle		-		-		61,157		612		47,947			-			-			48,559
Conversion of convertible notes payable to common stock		-		-		93,333		933		273,856			-			-			274,789
Issuance of stock to settle vested RSUs		-		-		126,532		1,265		(1,265	)		-			-			-
Share-based compensation		-		-		-		-		357,991			-			-			357,991
Net loss		-		-		-		-		-			(4,870,202	)		-			(4,870,202	)
Translation adjustment		-		-		-		-		-			-			(43,806	)		(43,806	)
Balance at June 30, 2023		-	$	-		20,292,624	$	202,926	$	59,423,678		$	(28,985,808	)	$	(245,459	)	$	30,395,337

Balance at December 31, 2021		-	$	-		9,625,133	$	96,251	$	20,203,972		$	(10,108,916	)	$	5,800		$	10,197,107
Share-based compensation		-		-		-		-		86,886			-			-			86,886
Net loss		-		-		-		-		-			(4,053,927	)		-			(4,053,927	)
Translation adjustment		-		-		-				-			-			(223,746	)		(223,746	)
Balance at June 30, 2022		-	$	-		9,625,133	$	96,251	$	20,290,858		$	(14,162,843	)	$	(217,946	)	$	6,006,320

See accompanying notes to condensed financial statements.

Table of Contents

Ainos, Inc.

Condensed Statements of Cash Flows

(Unaudited)

	Six months ended June 30,
	2023			2022
Cash flows from operating activities:
Net loss	$	(4,870,202	)	$	(4,053,927	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		2,423,274			2,378,835
Loss on inventory write-downs		57,474			-
Share-based compensation expense		357,991			86,886
Changes in operating assets and liabilities:
Accounts receivable		192,161			(29,881	)
Inventory		10,814			(670,507	)
Other current assets		(55,990	)		(775,909	)
Accrued expenses and other current and long-term liabilities		(684,372	)		838,484
Operating lease liabilities		(9,603	)		(10,125	)
Contract liabilities		-			606,866
Net cash used in operating activities		(2,578,453	)		(1,629,278	)
Cash flows from investing activities:
Purchase of property and equipment		(71,262	)		(424,557	)
Net cash used in investing activities		(71,262	)		(424,557	)
Cash flows from financing activities
Proceeds from convertible notes payable		1,000,000			850,000
Proceeds from convertible notes payable, related party		1,500,000			550,000
Proceeds from other notes payable, related party		-			800,000
Repayments of convertible notes payable, related party		(114,026	)		-
Repayments of other notes payable, related party		(200,000	)		-
Net cash provided by financing activities		2,185,974			2,200,000
Effect from foreign currency exchange		(28,651	)		(143,787	)
Net (decrease) increase in cash and cash equivalents		(492,392	)		2,378
Cash and cash equivalents at beginning of period		1,853,362			1,751,499
Cash and cash equivalents at end of period	$	1,360,970		$	1,753,877

Supplemental cash flow information:
Cash paid for interest	$	3,122		$	-
Noncash financing and investing activities
Purchase of equipment and intangible assets by issuing convertible notes payable to a related party	$	-		$	26,000,000
Conversion of convertible notes payable to common stock and accrued interest waived by convertible note holders	$	274,789		$	-
Issuance of common stock in exchange of vehicle	$	48,559		$	-
Payable for purchase of equipment	$	-		$	117,185

See accompanying notes to the condensed financial statements.

Table of Contents

Ainos, Inc.

Notes to Condensed Financial Statements

(Unaudited)

1. Description of Business

Organization and Business

Ainos, Inc. (the “Company”), incorporated in the State of Texas, is a diversified healthcare company focused on the development of novel point-of-care testing (POCT), therapeutics based on very low-dose interferon alpha (VELDONA), and synthetic RNA-driven preventative medicine. Our products include VELDONA clinical-stage human therapeutics, VELDONA Pet cytoprotein supplements, and telehealth-friendly POCTs powered by AI Nose technology platform.

The Company’s POCT platforms aim to provide connected, rapid and convenient testing of a broad range of health conditions. Building on its extensive research and development on VELDONA, the Company is focused on commercializing a suite of VELDONA-based products including VELDONA Pet cytoprotein supplements and VELDONA therapeutics for humans.

In 2021 and 2022, the Company acquired intellectual property from controlling shareholder, Ainos Inc., a Cayman Islands corporation (“Ainos KY”), and continues to expand its product portfolio into POCTs. Pivoting from the sales of COVID-19 POCT, the Company is commercializing POCTs that detect volatile organic compounds (VOC) emitted by the body, powered by the Company’s AI Nose technology platform. The Company’s lead VOC POCT candidate, Ainos Flora, aims to quickly and easily tests female vaginal health and certain common sexually transmitted infections (STIs).

Underwritten Public Offering

The Company’s registration statement related to its underwritten public offering (the “Offering”) was declared effective on August 8, 2022, and the Company’s common stock and warrants began trading on the Nasdaq Capital Market (the “Nasdaq”) on August 9, 2022 under the trading symbols “AIMD” and “AIMDW”, respectively. The Company completed its underwritten public offering of an aggregated 780,000 units at a public offering price of $4.25 per unit. Each unit issued in the offering consisted of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $4.25.

In connection with the Offering, the Company’s board of directors on April 29, 2022 and its shareholders on May 16, 2022 approved a 1-for-15 reverse stock split (the “Reverse Stock Split”) of the Company’s common stock prior to the effective date of the Offering. The par value and authorized shares of the Company’s common stock were not adjusted as a result of the Reverse Stock Split. All issued and outstanding common stock, restricted stock units (RSUs), outstanding convertible notes, warrants and options to purchase common stock and per share amounts contained in the financial statements have been retroactively adjusted to give effect to the Reverse Stock Split for all periods presented.

The Company filed a Certificate of Amendment to its Restated Certificate of Formation with the Secretary of State of Texas on August 8, 2022 that effectuated the Reverse Stock Split.

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (the “GAAP”) and pursuant to the accounting disclosure rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed financial statements should be read in conjunction with the financial statements and notes included in the Company’s audited financial statements as of and for the year ended December 31, 2022 contained in the Annual Report on Form 10-K filed with the SEC on April 3, 2023.

In the opinion of management, the accompanying condensed financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods. The results for the three and six months ended June 30, 2023 are not necessarily indicative of the results to be expected for any subsequent quarter, the year ending December 31, 2023, or any other period.

There have been no material changes to the Company’s significant accounting policies as described in the audited financial statements as of December 31, 2022.

Table of Contents

Use of Estimates

The preparation of condensed financial statements in conformity with GAAP requires management to make certain estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and disclosures as of the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates on various factors, including historical experience, and on various other assumptions that are believed to be reasonable under the circumstances, when these carrying values are not readily available from other sources. Significant items subject to estimates and assumptions include useful lives of property and equipment, valuation of stock option and warrants, and impairment testing of intangible assets. Actual results may differ from these estimates.

Liquidity

As of June 30, 2023, the Company had cash and cash equivalents of $1,360,970. The Company plans to finance its operations and development needs with its existing cash and cash equivalents, additional equity and/or debt financing arrangements, and expected revenue primarily from the sale of VELDONA Pet cytoprotein supplements to support the Company’s clinical trial activities, largely in connection with Ainos Flora and VELDONA therapeutics for humans. There can be no assurance that the Company will be able to obtain additional financing on terms acceptable to the Company, on a timely basis, or at all. If the Company is not able to obtain sufficient funds on acceptable terms when needed, the Company’s business, results of operations, and financial condition could be materially adversely impacted.

For the six months ended June 30, 2023, the Company generated a net loss of $4,870,202. The Company expects to continue incurring development expenses for the next twelve months as the Company advances Ainos Flora and VELDONA therapeutics for humans through clinical development until regulatory approval is received and the sales and marketing of the products are authorized.

The financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net operating losses in every year since inception and has an accumulated deficit as of June 30, 2023 of $28,985,808 and expects to incur additional losses and negative operating cash flows for at least the next twelve months. The Company’s ability to meet its obligations is dependent upon its ability to generate sufficient cash flows from operations and future financing transactions. Although management expects the Company will continue as a going concern, there is no assurance that management’s plans will be successful since the availability and amount of such funding is not certain. Accordingly, substantial doubt exists about the Company’s ability to continue as a going concern for at least one year from the issuance of these financial statements. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.

Segments

Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the chief operating decision maker (the “CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s Chief Executive Officer is the Company’s CODM. The CODM reviews financial information prepared on the basis of accounting policy disclosed in its annual financial statement for purposes of making operating decisions, allocating resources, and evaluating financial performance of the Company. As such, the Company has determined that it operates as one operating segment.

Impairment of Intangible Assets

The Company reviews its definite-lived intangibles and other long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be fully recoverable. When such events occur, management determines whether there has been impairment by comparing the anticipated undiscounted future net cash flows to the carrying value of the asset or asset group. If impairment exists, the assets are written down to their estimated fair value. No impairment of definite-lived intangible and long-lived assets was recorded for the three and six months ended June 30, 2023 and 2022.

Table of Contents

Recent Accounting Pronouncements Adopted

On January 1, 2023, the Company adopted Accounting Standards Update (the “ASU”) 2016-13 (the “ASU 2016-13”), Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which the Financial Accounting Standards Board (the “FASB”) issued in June 2016. The new standard changes the accounting for credit losses for financial assets and certain other instruments, including trade receivables and contract assets that are not measured at fair value through net income. Under legacy standards, the Company recognizes an impairment of receivables when it was probable that a loss had been incurred. Under the new standard pursuant to ASU 2016-13, the Company is required to recognize estimated credit losses expected to occur over the estimated life or remaining contractual life of an asset (which includes losses that may be incurred in future periods) using a broader range of information including reasonable and supportable forecasts about future economic conditions. The guidance is effective for smaller reporting companies (the “SRC”) as defined by the SEC for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years with early adoption permitted. The Company’s adoption of this new guidance did not have a material impact on the Company’s financial statements and related disclosure.

On January 1, 2023, the Company early adopted ASU 2020-06 (the “ASU 2020-06”), Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 as issued by FASB in August 2020 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for SRC’s fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. The Company’s early adoption of this new guidance did not have a material impact on its financial statements and related disclosures.

Accounting Standards Issued but Not Yet Adopted

No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s financial statements.

3. Cash and Cash Equivalents

As of June 30, 2023 and December 31, 2022, cash and cash equivalents consist of cash on hand and cash in bank which is potentially subject to concentration of credit risk. Such balance is maintained at financial institutions that management determines to be of high-credit quality. Cash accounts at each institution are insured by the Federal Deposit Insurance Corporation in the U.S.A or Central Deposit Insurance Corporation in Taiwan up to certain limits. At times, such deposits may be in excess of the insurance limit. The Company has not experienced any losses on its deposits.

4. Inventory

Inventory stated at cost, net of reserve, consisted of the following:

	June 30,		December 31,
	2023		2022
Raw materials	$	354,175	$	393,253
Work in process		67,736		111,119
Finished goods		106,203		90,850
Total	$	528,114	$	595,222

Inventory write-downs to estimated net realizable values were $14,694 and $ 57,474 for the three and six months ended June 30, 2023, respectively, compared to nil for the three and six months ended June 30, 2022.

Table of Contents

5. Convertible Notes Payable and Other Notes Payable

As of June 30, 2023 and December 31, 2022, the respective notes payable was as follows:

	June 30, 2023		December 31, 2022
Convertible notes payable, related party – current	$	-	$	376,526
Other notes payable, related party - current		684,000		884,000
March 2025 Convertible Notes, related party - noncurrent		1,500,000		-
March 2025 Convertible Notes - noncurrent		1,000,000		-
	$	3,184,000	$	1,260,526

The Company received funding in the form of convertible promissory note from Dr. Stephen T. Chen, the former Chief Executive Officer or Chen, (the “Chen Note”) in 2016 for the purpose of supporting working capital. The Chen Note is payable on demand and can be converted into common stock of the Company any time at the conversion price of $2.52 or $2.81 per share. The Chen Note bears an interest rate of 0.75% or 0.65%. During the three months ended June 30, 2023, $114,026 of the Chen Note was paid off in cash and the remaining $262,500 of the Chen Note was assigned by Chen to unrelated parties who exercised the conversion right and converted the Chen Note into 93,333 shares of common stock of the Company. The accrued interest expense related to the converted Chen Note was waived by Chen and the assigned parties.

The other notes payable were issued to Ainos KY, which is the controlling shareholder of the Company, in exchange for $800,000 in cash to support working capital of the Company in March 2022 (the “KY Note”). The Company paid off $200,000 of the KY Note during the six months ended June 30, 2023. Another notes payable was issued to i2China in exchange for consulting service in 2020 (the “i2China Note”) which remains outstanding for the amount of $84,000 as of June 30, 2023. Both other notes payable bear an interest rate of 1.85% per annum.

All of the aforementioned convertible promissory notes and other notes payable are unsecured and due upon maturity. The Company may prepay the notes in whole or in part at any time. The holder of convertible notes has the option to convert some or all of the unpaid principal and accrued interest to common stock of the Company.

In July and August 2023, the Company paid off $300,000 of the KY Note and $42,000 of the i2China Note together with the accrued interest and the remaining principal amount is $300,000 and $42,000 for KY Note and i2China Note, respectively.

March 2025 Convertible Notes

On March 13, 2023, the Company entered into two convertible promissory note purchase agreements pursuant to Regulation S of the Securities Act of 1933 in the total principal amount of $3,000,000 with the following investors (the “March 2025 Convertible Notes” or “Notes”).

Convertible Note Issued to ASE Test, Inc. (the “ASE Note”)

Pursuant to the aforementioned agreement, ASE Test, Inc., a shareholder of Ainos KY, committed to pay a total aggregate amount of $2,000,000 to the Company in exchange for convertible promissory note(s) in three tranches in the amounts of $1,000,000 (the “First Tranche”), $500,000 (the “Second Tranche”), and $500,000 (the “Third Tranche”) which is conditioned, among other things, on the Company achieving certain business milestones. As of June 30, 2023, the Company received $1,500,000 in cash for the First Tranche and Second Tranche upon achieving pre-defined business milestones. The Third Tranche is pending on the achievement of milestone by the Company.

Convertible Note Issued to Li-Kuo Lee (the “Lee Note”)

The Company issued a convertible note to an unrelated party, Li-Kuo Lee in exchange of $1,000,000 in cash. As of June 30, 2023, the Company received the full amount of the payment.

The March 2025 Convertible Notes will mature in two years from the issuance dates, bearing interest at the rate of 6% compounded interest per annum. At any time after the issuance and before the maturity date, the Notes are convertible into the common stock of the Company at the conversion price of $1.50 per share, subject to anti-dilutive adjustment as set forth in the Notes. Unless previously converted, the Company shall repay the outstanding principal amount plus all accrued and unpaid interest on the maturity date. The Notes shall be an unsecured general obligation of the Company.

The total interest expense of convertible notes payable and other notes payable for the three and six months ended June 30, 2023 were $37,991 and $44,924, respectively, compared with the three and six months ended June 30, 2022 of $18,602 and $34,486, respectively. As of June 30, 2023 and December 31, 2022, the unpaid accrued interest expense was $64,795 and $35,282, respectively, among which $37,562 and nil was long-term liabilities, respectively.

Table of Contents

6. Stockholders’ Equity

Common Stock

During the three months ended June 30, 2023, the Company issued an additional 281,022 shares of common stock as a result of delivering 126,532 shares to settle vested RSUs, an additional 93,333 shares for the conversion of Chen Note (see Note 5), and 61,157 shares in exchange for a vehicle with a related party (see Note 11). As of June 30, 2023, there were 20,292,624 shares of common stock legally issued and outstanding.

Warrants

As of June 30, 2023 and December 31, 2022, warrants issued and outstanding in connection with financing are summarized as below:

	June 30,		December 31,
(In number of shares)	2023		2022
Public warrant with exercise price of $4.25		897,000		897,000
Private warrant with exercise price of $4.675		39,000		39,000
Total		936,000		936,000

As disclosed in Note 1, the Company issued public warrants together with common stocks in connection with its underwritten public offering effective August 8, 2022. The Company further issued private warrants to Maxim Group LLC, as representative of underwriter pursuance to an underwriting agreement. Each warrant has a contractual term of 5 years, expiring on August 8, 2027, and can be exercised for the purchase of one share of common stock of the Company.

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the instruments’ specific terms and applicable authoritative guidance in ASC 480, Distinguishing Liabilities from Equity (the “ASC480), and ASC 815, Derivatives and Hedging (the “ASC 815”). The assessment considers whether the instruments are free standing financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the instruments meet all of the requirements for equity classification under ASC 815, including whether the instruments are indexed to the Company’s own common shares and whether the instrument holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent period end date while the instruments are outstanding. Management has concluded that the warrants issued in connection with the underwritten public offering qualify for equity accounting treatment and recorded in the additional paid-in capital.

In addition, the warrant issued by the Company to i2China in 2020 in exchange for consulting services is accounted for under ASC 718, Compensation - Stock Compensation. Refer to Note 8.

As of June 30, 2023, none of the warrants have been exercised nor have expired.

7. Revenue

Revenue is recognized upon shipment of products based upon contractually stated pricing at standard payment terms within 30 days. The revenue generated by product sales is recognized at point in time. For the three and six months ended June 30, 2023 and 2022, the Company generated revenue solely from sales of COVID-19 Antigen Rapid Test Kits in the Taiwan market. There was no revenue recognized from performance obligation satisfied or partially satisfied in prior periods, nor were there any unsatisfied performance obligations as of June 30, 2023 and December 31, 2022.

Table of Contents

8. Share-Based Compensation

2023 Stock Incentive Plan

The Company effectuated an amendment to its 2021 Stock Incentive Plan, now restated as the Company 2023 Stock Incentive Plan (the “2023 SIP” or “Plan”) which includes, among other things, a change in the number of reserved shares under the Plan. Under the 2023 SIP, subject to a change in capital structure or a change in control, the aggregate number of shares which may be issued or transferred pursuant to awards under the Plan will be equal to up to twenty percent (20%) of shares of outstanding common stock of the Company existing as of December 31^st of the previous calendar year (the “Plan Share Reserve”). Upon the effectiveness of the 2023 SIP on June 14, 2023, the aggregate number of shares which may be issued pursuant to awards under the Plan is 4,355,376 shares of common stock, including shares that remained available for grant under the 2021 Stock Incentive Plan. As of June 30, 2023, no shares have been granted under the 2023 SIP.

2021 Stock Incentive Plan

On September 28, 2021, the Company’s board of directors, and on May 16, 2022, its shareholders approved the 2021 Stock Incentive Plan (the “2021 SIP”). During the period from January 1, 2023 up to the date that the prior plan was superseded by the 2023 SIP, no shares were granted under the 2021 SIP.

2021 Employee Stock Purchase Plan

On September 28, 2021, the Company’s board of directors, and on May 16, 2022, its shareholders approved the 2021 Employee Stock Purchase Plan (the “2021 ESPP”). As of June 30, 2023, no shares were issued under the 2021 ESPP.

Restricted Stock Units (“RSUs”)

RSUs entitle the recipient to be paid out an equal number of common stock shares upon vesting. The fair value of RSUs is based on market price of the underlying stock on the date of grant. A summary of the Company’s RSUs activity and related information for the three and six months ended June 30, 2022 was Nil and for the three and six months ended June 30, 2023 was as follows:

	Number of Share			Weighted-Average Grant Date Fair Value Per Share
Unvested balance at December 31, 2022		800,000		$	2.42
RSUs granted		-		$	-
RSUs vested*		(29,332	)	$	11.10
RSUs forfeited		(38,000	)	$	1.43
Unvested balance at March 31, 2023		732,668		$	2.12
RSUs granted		-		$	-
RSUs vested**		(101,100	)	$	1.34
RSUs forfeited		(34,850	)	$	1.27
Unvested balance at June 30, 2023		596,718		$	2.30

* The common stock underlying the vested RSUs was delivered to grantees during the three months ended June 30, 2023.

** 3,900 shares of vested RSUs have not been settled by issuance of common shares to grantees as of June 30, 2023.

Stock Options and Warrants

During the three and six months ended June 30, 2023 and 2022, no shares were granted, forfeited, expired or exercised. As of June 30, 2023, there were 36,666 shares in the form of stock options and 30,174 shares in the form of warrants outstanding.

Table of Contents

Share-Based Compensation Expense

Shared-based compensation expense for the three and six months ended June 30, 2023 were $137,159 and $357,991, respectively, compared to the three and six months ended June 30, 2022 amount of $43,443 and $86,886, respectively.

As of June 30, 2023, the total unrecognized compensation cost related to outstanding RSUs, stock options and warrants was $1,439,499, which the Company expects to recognize over a weighted-average period of 1.85 years.

9. Income Taxes

The Company did not record a federal, state, or foreign income tax provision or benefit for the three or six months ended June 30, 2023 and 2022 due to the expected loss before income taxes to be incurred for the years ended December 31, 2023 and 2022, as well as the Company’s continued maintenance of a full valuation allowance against its net deferred tax assets due to its historical deficit.

10. Net Loss per Common Share

The following table sets forth the computation of the basic and diluted net loss per share attributable to common stockholders:

	Three Months Ended June 30,						Six Months Ended June 30,
	2023			2022			2023			2022
Net loss attributable to common stockholders, basic and diluted	$	(2,349,727	)	$	(1,954,032	)	$	(4,870,202	)	$	(4,053,927	)
Weighted-average number of shares used in computing net loss per share attributable to common stockholders, basic and diluted		20,095,705			9,625,133			20,053,886			9,625,133
Net loss per share attributable to common stockholders, basic and diluted	$	(0.12	)	$	(0.20	)	$	(0.24	)	$	(0.42	)

The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding because they would be anti-dilutive:

	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Option and RSUs to purchase common stock		633,384		36,666		633,384		36,666
Warrants to purchase common stock		966,174		30,174		966,174		30,174
Convertible note to purchase common stock		1,666,667		9,197,405		1,666,667		9,197,405
Total potential shares		3,266,225		9,264,245		3,266,225		9,264,245

11. Related Party Transactions

The following is a summary of related party transactions that met our disclosure threshold:

Asset Purchase Agreement

Ainos KY and the Company entered into an Asset Purchase Agreement dated as of November 18, 2021 (the “Asset Purchase Agreement”), as modified by an Amended and Restated Asset Purchase Agreement dated as of January 29, 2022 (the “Amended Asset Purchase Agreement”).

Pursuant to the Asset Purchase Agreement, the Company acquired certain intellectual property assets and certain manufacturing, testing, and office equipment for a total purchase price of $26,000,000 that included $24,886,023 for intangible intellectual property assets and $1,113,977 for equipment. As consideration the Company issued to Ainos KY a convertible promissory note in the principal amount of $26,000,000 upon closing on January 30, 2022 (the “APA Convertible Note”). Ainos KY converted all of the APA Convertible Note on or about August 8, 2022 upon the Company’s up-listing to the Nasdaq Capital Markets.

Table of Contents

Working Capital Advances

Refer to Chen Note, KY Note and ASE Note in Note 5 which proceeds were used for working capital advances. The total interest expense incurred in related to the notes for the three and six months ended June 30, 2023 were $23,031 and $26,841, respectively, compared to $18,602 and $34,486, respectively, for the three and six months ended June 30, 2022. As of June 30, 2023 and December 31, 2022, unpaid accrued interest expenses were $46,712 and $35,282, respectively.

Purchase and Sales

Ainos COVID-19 Test Kits Sales and Marketing Agreement with Ainos KY

On June 14, 2021, the Company entered into an exclusive agreement with Ainos KY to serve as the master sales and marketing agent for the Ainos COVID-19 Antigen Rapid Test Kit and COVID-19 Nucleic Acid Test Kit which were developed and will be manufactured by Taiwan Carbon Nano Technology Corporation (the “TCNT”), a controlling shareholder of Ainos KY (the “Sales and Marketing Agreement”). On June 7, 2021, the Taiwan Food and Drug Administration (the “TFDA”) approved emergency use authorization (the “EUA”) to TCNT for the Ainos COVID-19 Antigen Rapid Test Kit that will be sold and marketed under the “Ainos” brand in Taiwan. On June 21, 2022, the Company began marketing the Ainos SARS-CoV-2 Antigen Rapid Self-Test (together with Ainos COVID-19 Antigen Rapid Test Kit, the “COVID-19 Antigen Rapid Test Kits”) under a separate EUA issued by the TFDA to TCNT on June 13, 2022.

The Company incurred costs associated with manufacturing COVID-19 Antigen Rapid Test Kits by TCNT pursuant to the Sales and Marketing Agreement, totaling nil and $46,635 for the three and six months ended June 30, 2023, respectively, compared with the amount for the three and six months ended June 30, 2022 of $483,992 and $870,404, respectively. As of June 30, 2023 and December 31, 2022, the accounts payable to TCNT were nil and $24,365, respectively; the prepayment to TCNT were $90,519 and nil, respectively.

COVID-19 Antigen Rapid Test Kits Sales

The Company sold COVID-19 Antigen Rapid Test Kits to affiliates of ASE Test Inc., totaling $12,541 and $12,541 for the three and six months ended June 30, 2023, respectively, compared with the amount for the three and six months ended June 30, 2022 of $401,259 and $482,359, respectively. As of June 30, 2023, and December 31, 2022, the accounts receivable to aforementioned related parties were nil and $177,595, respectively.

Product Co-development Agreement

Pursuant to a five-year Product Co-development Agreement effective on August 1, 2021 (the “Product Co-Development Agreement”) with TCNT, the development expenses incurred were $74,733 and $152,196 for the three and six months ended June 30, 2023, respectively, compared to $206,748 and $374,170 for the three and six months ended June 30, 2022, respectively. As of June 30, 2023 and December 31, 2022, the accounts payable were $25,089 and $70,113, respectively. Under the agreement, the Company made deposits of $31,071 and $31,490 to TCNT as of June 30, 2023 and December 31, 2022, respectively.

Miscellaneous

On April 26, 2023, the Company issued a total of 61,157 shares of common stock to Ting-Chuan Lee, a director of the Company, pursuant to a purchase and sale agreement relating to the Company’s acquisition of a vehicle. The purchase price was determined by the market price of the vehicle in the amount of $48,559.

The Company engaged Ms. Chien-Hsuan Huang as a medical device development consultant in September 2022. Ms. Huang is the spouse of one of the board of directors of the Company. The R&D expense was $19,618 and $39,344 for the three and six months ended June 30, 2023, respectively.

12. Commitments and Contingencies

The Company operates in an industry characterized by extensive patent litigation. Competitors may claim that the Company’s products infringe upon their intellectual property. Resolution of patent litigation or other intellectual property claims is typically time consuming and costly and can result in significant damage awards and injunctions that could prevent the manufacture and sale of the affected products or require the Company to make significant royalty payments in order to continue selling the affected products. As of June 30, 2023, there were no such commitments or contingencies.

13. Subsequent Events

On August 9, 2023, the Company entered into a Co-Development Agreement (the “Agreement”) with Nisshinbo Micro Devices Inc., a Japan corporation (“NISD”), and Taiwan Inabata Sangyo Co., Ltd., a Taiwan corporation (“Inabata”). Pursuant to the Agreement, NISD will outsource development of the odor platform and delivery of gas sensor products to the Company. Inabata is responsible for coordinating the co-development effort between NISD and the Company.

The Company will provide the deliverables in phases and performance obligations will be satisfied upon NISD’s acceptance. The total contract price is variable based on the quantity specified by NISD for future purchase orders. The Agreement is effective August 9, 2023 and expires on August 31, 2026.

Table of Contents

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The unaudited condensed financial statements and this Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2022 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our 2022 Annual Report. In addition to historical information, this discussion and analysis contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These forward-looking statements are subject to risks and uncertainties, including those set forth under “Part I. Item 1A. Risk Factors” in our 2022 Annual Report, “Part II. Item 1A. Risk Factors” in this Quarterly Report, and elsewhere in this Quarterly Report, that could cause actual results to differ materially from historical results or anticipated results.

When used in this Quarterly Report, all references to "Ainos," the "Company," "we," "our" and "us" refer Ainos, Inc.

Overview

Ainos, Inc. (the “Company”, “we” or “us”), incorporated in the State of Texas, is a diversified healthcare company focused on the development of novel point-of-care testing (POCT), therapeutics based on very low-dose interferon alpha (VELDONA), and synthetic RNA-driven preventative medicine. Our products include VELDONA clinical-stage human therapeutics, VELDONA Pet cytoprotein supplements, and telehealth-friendly POCTs.

The Company’s POCT platforms are designed to provide rapid and convenient testing of a broad range of health conditions. Building on its extensive research and development on VELDONA, the Company is focused on commercializing a suite of VELDONA-based products including VELDONA Pet cytoprotein supplements and VELDONA therapeutics for humans.

In 2021 and 2022, the Company acquired intellectual property from controlling shareholder, Ainos Inc., a Cayman Islands corporation (“Ainos KY”), and continues to expand its product portfolio into POCTs. Pivoting from the sales of COVID-19 POCT, the Company is commercializing POCTs that detect volatile organic compounds (VOC) emitted by the body, powered by the Company’s AI Nose technology platform. The Company’s lead VOCT POCT candidate, Ainos Flora, aims to quickly and easily tests female vaginal health and certain common sexually transmitted infections (STIs).

Our Portfolio of Products

Our portfolio of products is currently comprised of the following:

	•	COVID-19 Antigen Rapid Test Kit. We currently market and sell COVID-19 antigen rapid test kits in Taiwan under emergency use authorization (“EUA”) issued by the Taiwan Federal and Drug Administration (“TFDA”) for healthcare professional use and for self-test use. We market the test kits under the Ainos brand name. The kit is manufactured by TCNT, our product co-developer.

	•	VOC POCT – Ainos Flora. Our Ainos Flora device, powered by the Company’s proprietary AI Nose technology (“AI Nose”) is currently under clinical study in Taiwan. The device is intended to perform a non-invasive test for female vaginal health and certain common STIs within a few minutes. A companion app is also being developed that enables users to conveniently manage test results. We believe Ainos Flora provides connected, convenient, discreet, rapid testing in a point-of-care setting.

	•	VOC POCT – Ainos Pen. Our Ainos Pen device is designed to be a cloud-connected, multi-purpose, portable breath analyzer that is intended to monitor health conditions within minutes, powered by AI Nose. We expect consumers to be empowered to share their test results with their physicians through in-person and telehealth medical consultations.

	•	VOC POCT – CHS430. The CHS430 device, powered by AI Nose, is intended to provide non-invasive testing for ventilator-associated pneumonia within few minutes, as compared to current standard of care invasive culture tests that typically take more than two days to provide results. We plan to be the exclusive sales agent for CHS430, pursuant to our Product Co-Development Agreement with our co-developer, TCNT, who will manufacture the product.

	•	Very Low-Dose Oral Interferon Alpha (“VELDONA”). VELDONA is a low-dose oral interferon alpha (“IFN-α”) formulation based on nearly four decades of the Company’s research on IFN-α’s broad treatment applications. Our pipeline candidates under development for human indications include thrombocytopenia, Sjögren’s syndrome, aphthous stomatitis, chemotherapy-induced stomatitis, common cold, oral warts for human immunodeficiency virus (HIV) seropositive patients, influenza, oral treatment for COVID-19. We intend to explore various business opportunities, including out-licensing, to advance these indications. •VELDONA Pet. Leveraging our VELDONA technology, we recently launched five VELDONA Pet cytoprotein health supplements for pet dogs and cats. Our VELDONA Pet product line is formulated to address a variety of health issues in dogs and cats, including skin, gum, emotion, discomfort caused by allergies, eye; and weight-related issues. We are currently launching sales and marketing in Taiwan and plan to develop sales and marketing opportunities in other Asian regions and the U.S.A.

	•	Synthetic RNA (“SRNA”). We are developing a SRNA technology platform in Taiwan with a long-term goal of developing next-generating precision treatments and rapid tests.

Table of Contents

An integral part of our operating strategy is to create multiple revenue streams through commercializing our product portfolio and leveraging our intellectual property patents. Our recent launch of VELDONA Pet, a series of health supplements for pet dogs and cats based on VELDONA formulation, is our latest effort to execute the diversification strategy.

In 2023, we are prioritizing sales and marketing of VELDONA Pet, commercializing our lead VOC POCT candidate, Ainos Flora, and pursuing out-licensing of our VELDONA human drug candidates. We are initiating sales and marketing of VELDONA Pet in Taiwan and intend to explore commercial opportunities in other Asian regions and the U.S.A. We recently assigned Topmed International Biotech Co. to exclusively market VELDONA Pet in Taiwan.

As of June 30, 2023, we had available cash and cash equivalents of $1,360,970. We anticipate business revenues and further potential financial support from external sources to fund our operations over the next twelve months. We have based this estimate on assumptions that may prove to be incorrect, and we could exhaust our available capital resources sooner than we expect. See “Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources” for additional information. To finance our continuing operations, we will need to raise additional capital, which cannot be assured.

Impact of COVID-19 on Our Business

Substantially all of our operating revenue comes from the sale of COVID-19 test kits in Taiwan under emergency use authorization. We recently launched new product line called VELDONA Pet. We plan to generate sales revenue from VELDONA Pet initially in Taiwan and explore commercialization opportunities in other Asian regions and the U.S.A.

We believe that during the COVID-19 pandemic, consumers have become increasingly familiar with at-home tests. Moving forward, people may seek additional at-home tests to manage other infections as quickly as possible. Home self-testing and self-collection have been increasingly available for other infections such as vaginal or STIs. We believe this new user behavior, supported by a variety of telehealth platforms, will become increasingly accommodative for our other POCT products as COVID-19 becomes an endemic.

We are continuing to monitor the potential impact of COVID-19, but we cannot be certain the future impact on our business, financial condition, results of operations and prospects.

Results of Operations for Quarter Ended June 30, 2023 (“Q2 2023”) and June 30, 2022 (“Q2 2022”):

	Three months ended June 30,						Change
	2023			2022			Amount			%

Revenues	$	28,555		$	636,627		$	(608,072	)	(96		%)
Cost of revenues		(55,817	)		(318,963	)		263,146			83	%
Gross (loss) profit		(27,262	)		317,664			(344,926	)	(109		%)
Operating expenses:
Research and development expenses		1,671,187			1,634,856			36,331			2	%
Selling, general and administrative expenses		618,149			627,104			(8,955	)	(1		%)
Total operating expenses		2,289,336			2,261,960			27,376			1	%
Loss from operations		(2,316,598	)		(1,944,296	)		(372,302	)		19	%

Non-operating income (expenses), net:
Interest expense		(40,311	)		(18,796	)		(21,515	)		114	%
Other income, net		7,182			9,060			(1,878	)	(21		%)
Total non-operating expenses, net		(33,129	)		(9,736	)		(23,393	)		240	%

Net loss before income taxes		(2,349,727	)		(1,954,032	)		(395,695	)		20	%
Provision for income taxes		-			-			-			-
Net loss	$	(2,349,727	)	$	(1,954,032	)	$	(395,695	)		20	%

Table of Contents

Revenues, Cost and Gross Profit (Loss)

The Company reported $28,555, and $636,627 in revenue in Q2 2023 and Q2 2022, respectively, from product sales of Ainos COVID-19 Antigen Rapid Test Kits in Taiwan. The decrease of revenue in Q2 2023 reflected a slowdown of COVID-19 infection in Taiwan which resulted in a decrease in selling price and sales volume.

The cost of revenue relating to product sales in Q2 2023 was $55,817 compared to $318,963 in Q2 2022. The decrease of cost of revenue was due to a decrease in sales volume but offset by an increase in inventory loss.

Gross (loss) profit from product sales in Q2 2023 was $(27,262) as compared to $317,664 in Q2 2022. The gross loss was due to a decrease in sales volume and selling price as well as recognition of inventory loss in Q2 2023.

Research and Development (R&D) Expenses

R&D expenses in Q2 2023 and Q2 2022 were $1,671,187 and $1,634,856, respectively. The slight increase of $36,331 (2%) was due to increased expenses associated with staffing expenditures (including share-based compensation) and professional expense, but offset by a decrease in clinical trial fees. We expect that our R&D expenses related to clinical trials will continue to grow as we further develop VOC POCT and VELDONA drug candidates and increase the pace of clinical trials previously delayed during the COVID-19 pandemic.

The share-based compensation expense and the depreciation and amortization expense in Q2 2023 and Q2 2022 were $1,210,429 and 1,155,754, respectively. When excluding these non-cash expenses, R&D expenses slightly decreased to $460,758 in Q2 2023 from $479,102 in Q2 2022 due to limitations on recruiting patients for clinical trials for VOC POCT and VELDONA human related drug candidates, but offset by an increase in R&D personnel expense.

Selling, General and Administrative (SG&A) Expenses

SG&A expenses were $618,149 and $627,104 in Q2 2023 and Q2 2022, respectively, reflecting a slight decrease of $8,955 (1%).

The share-based compensation expense and the depreciation and amortization expense in Q2 2023 and Q2 2022 were $121,025 and $125,223, respectively. When excluding these non-cash expenses, SG&A expenses slightly decreased to $497,124 in Q2 2023 compared to $501,881 in Q2 2022.

Operating Loss

The Company’s operating loss was $2,316,598 and $1,944,296 in Q2 2023 and Q2 2022, respectively, reflecting a $372,302 (19%) increase in operating loss between the reporting periods. We incurred a gross loss in product sales that did not offset operating expenses. We continued to invest resources to execute our growth strategy and product roadmap to improve our profitability.

Table of Contents

Interest Expense

In Q2 2023, interest expense was $40,311 compared to $18,796 in Q2 2022. The increase in interest expense was due to accrued interest for convertible notes issued in March 2023 bearing a higher interest rate.

Net Loss

Net loss was $2,349,727 in Q2 2023 compared to $1,954,032 in Q2 2022, resulting in a $395,695 (20%) increase in net loss attributable to shareholders of our common stock. The net loss was due to a gross loss in product sales post COVID-19 pandemic.

Results of Operations for the Six Months Ended June 30, 2023 (“H1 2023”) and June 30, 2022 (“H1 2022”):

	Six months ended June 30,						Change
	2023			2022			Amount			%

Revenues	$	77,719		$	723,828		$	(646,109	)	(89		%)
Cost of revenues		(156,665	)		(360,042	)		203,377		(56		%)
Gross (loss) profit		(78,946	)		363,786			(442,732	)	(122		%)
Operating expenses:
Research and development expenses		3,370,070			3,212,310			157,760			5	%
Selling, general and administrative expenses		1,380,614			1,178,834			201,780			17	%
Total operating expenses		4,750,684			4,391,144			359,540			8	%
Loss from operations		(4,829,630	)		(4,027,358	)		(802,272	)		20	%

Non-operating income (expenses), net:
Interest expense		(49,585	)		(35,483	)		(14,102	)		40	%
Other income, net		9,013			8,914			99			1	%
Total non-operating expenses, net		(40,572	)		(26,569	)		(14,003	)		53	%

Net loss before income taxes		(4,870,202	)		(4,053,927	)		(816,275	)		20	%
Provision for income taxes		-			-
Net loss	$	(4,870,202	)	$	(4,053,927	)	$	(816,275	)		20	%

Revenues, Cost and Gross Profit (Loss)

The Company reported $77,719 of revenue for the six months ended June 30, 2023, as compared to $723,828 for the six months ended June 30, 2022 from product sales of Ainos COVID-19 Antigen Rapid Test Kits in Taiwan. The decrease of revenue in H1 2023 reflected a slowdown of COVID-19 infection in Taiwan resulting in a decrease in selling price and sales volume.

The cost of revenue relating to product sales for the six months ended June 30, 2023 was $156,665 compared to $360,042 for the six months ended June 30, 2022. The decrease of cost of revenue was due to a decrease in sales volume but offset by an increase of approximately $57,000 in inventory loss and approximately $20,000 in idle manufacturing capacity.

Gross (loss) profit from product sales for the six months ended June 30, 2023 was $(78,946) as compared to $363,786 for the six months ended June 30, 2022. The gross loss was due to a decrease in sales volume and selling price as well as recognition of inventory loss and idle capacity cost in H1 2023.

Research and Development (R&D) Expenses

R&D expenses for the six months ended June 30, 2023 and 2022 were $3,370,070 and $3,212,310, respectively. The $157,760 (5%) increase was largely due to increased expenses associated with staffing expenditures (including share-based compensation) and professional expense, but offset by a decrease in clinical trial fees. We expect that our R&D expenses related to clinical trials will continue to grow as we further develop VOC POCT and VELDONA drug candidates and increase the pace of clinical trials previously delayed during the COVID-19 pandemic.

The share-based compensation expense and the depreciation and amortization expense in H1 2023 and H1 2022 were $2,405,414 and 2,291,966, respectively. When excluding these non-cash expenses, R&D expenses slightly increased to $964,656 in H1 2023 from $920,344 in H1 2022 due to an increase in R&D personnel expense, but offset by a decrease in clinical trial fees due to delays caused by the COVID-19 pandemic.

Table of Contents

Selling, General and Administrative (SG&A) Expenses

SG&A expenses were $1,380,614 and $1,178,834 for the six months ended June 30, 2023 and 2022, respectively. The $201,780 (17%) increase was largely due to increased expenses associated with share-based compensation as the Company granted RSUs to employees and board of directors in the second half of 2022 and fully recorded amortized compensation expense in H1 2023.

The share-based compensation expense and the depreciation and amortization expense in H1 2023 and H1 2022 were $327,495 and 145,447, respectively. When excluding these non-cash expenses, SG&A expenses slightly increased to $1,053,119 in H1 2023 compared to $1,033,387 in H1 2022.

Operating Loss

The Company’s operating loss was $4,829,630 and $4,027,358 in H1 2023 and H1 2022, respectively, reflecting an $802,272 (20%) increase in operating losses between the reporting periods. We incurred a gross loss in product sales that did not offset operating expenses. We continued to invest resources to execute our growth strategy and product roadmap to improve our profitability.

Interest Expense

In H1 2023, interest expense was $49,585 compared to $35,483 in H1 2022. The increase in interest expense was due to accrued interest for convertible notes issued in March 2023 offset by a decrease of interest expense as a result of settlement of convertible notes during H1 2023.

Net Loss

Net loss was $4,870,202 in H1 2023 compared to $4,053,927 in H1 2022, resulting in an $816,275 (20%) increase in net loss attributable to our shareholder of common stock. The net loss was due to gross loss in product sales post COVID-19 pandemic while our VEDOLNA Pet sales launched in July 2023.

Liquidity and Capital Resources

As of June 30, 2023 and December 31, 2022, the Company had available cash of $1,360,970 and $1,853,362, respectively.

The following table summarizes our cash flow during the six months period ended June 30, 2023 and 2022:

	Six months ended June 30,
	2023			2022
Net cash used in operating activities		(2,578,453	)		(1,629,278	)
Net cash used in investing activities		(71,262	)		(424,557	)
Net cash provided by financing activities		2,185,974			2,200,000

Operating activities:

Cash used in operating activities increased by $949,175 in H1 2023 compared to H1 2022. Our net loss for H1 2023 increased by $816,275 primarily due to a gross loss from COVID-19 antigen test kit sales as a result of slow-down of COVID-19 infection in Taiwan. The operating cash outflow as a result of changes in operating assets and liabilities was mainly attributable to:

	·	No cash out expenses including share-based compensation, depreciation and amortization, and loss on inventory write-downs increased approximately by $373,000
	·	Working capital injected into accounts receivable, inventories and other current assets increased by approximately $1,623,000
	·	Working capital injected into accrued expenses, lease liabilities and other current and long-term liabilities decreased by approximately $2,129,000.

Table of Contents

Investing activities

Cash used for investing activities in H1 2023 was $71,262 compared to $424,557 in H1 2022, respectively, due to lower levels of R&D equipment and office facility acquisition, major investments in 2022.

Financing activities

Cash received from financing activities was $2,185,974 and $2,200,000 in H1 2023 and H1 2022, respectively. The $14,026 decrease was primarily reflected by the following:

	·	Repayment of convertible notes and other notes payable increased $314,026; but
	·	Proceeds from convertible notes and other notes payable increased by $300,000.

As disclosed in Note 5 Convertible Notes Payable and Other Notes Payable, we received $2.5 million in proceeds from convertible note financing in March 2023. Meanwhile, we made partial cash payment of the KY Note and Chen Note during H1 2023.

In 2023, we project an increase in the pace of clinical trial spending to advance our VOC POCT and VELDONA drug candidates and expect to invest more in R&D activities. We also plan to allocate sales and marketing efforts for VELDONA Pet.

The Company anticipates that cash reserves, business revenues, and potential debt financing through convertible and non-convertible notes will fund the Company’s operations over the next twelve months. There can be no assurance that we will be successful in our efforts to make the Company profitable. If those efforts are not successful, the Company may raise additional capital through the issuance of equity securities, debt financings or other sources to further implement its business plan. However, if such financing is not available when needed and at adequate levels, the Company will need to reevaluate its operating plan.

Critical Accounting Policies and Significant Management Estimates

Our management’s discussion and analysis of our financial condition and results of operations are based on our unaudited condensed financial statements, which have been prepared in accordance with the accounting principles generally accepted in the United States, or U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses.

We evaluate our estimates and judgments, including those related to inventory valuation, useful lives of property and equipment, valuation of stock option and warrants, and impairment testing of intangible assets, on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

There have been no material changes to our critical accounting policies and estimates as compared to the critical accounting policies and estimates disclosed in “Management’s Discussion and Analysis - Critical Accounting Policies and Significant Management Estimates” of our 2022 Annual Report, except for those accounting subjects discussed in the Notes, if any, to the unaudited condensed financial statements included in this Quarterly Report on Form 10-Q.

ITEM 3. Quantitative and Qualitative Disclosures About Market Risk

We are a smaller reporting company as defined in Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this Item 3.

Table of Contents

ITEM 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, have evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on the evaluation of our disclosure controls and procedures, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of June 30, 2023.

Changes in Internal Control over Financial Reporting

There were no changes in our internal controls over financial reporting during the period covered by this Quarterly Report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II - OTHER INFORMATION

ITEM 1. Legal Proceedings

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. As of the date of this report, we were not aware of any material legal proceedings or claims involving the Company.

ITEM 1A. Risk Factors

This Quarterly Report contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed in this Quarterly Report. Factors that could cause or contribute to these differences include, but are not limited to, those discussed below and elsewhere in this Quarterly Report.

You should carefully consider the risk factors disclosed in our Form 10-K for the period ended December 31, 2022 (the “2022 Annual Report”), together with all other information in this Quarterly Report, including our unaudited condensed financial statements and notes thereto, and in our other filings with the Securities and Exchange Commission. If any of the following risks, or other risks not presently known to us or that we currently believe to not be significant, develop into actual events, then our business, financial condition, results of operations or prospects could be materially adversely affected. If that happens, the market price of our common stock could decline, and stockholders may lose all or part of their investment.

There are no material changes to the risk factors as previously disclosed in our 2022 Annual Report, incorporated herein by this referenced, which was filed with the Securities and Exchange Commission on April 3, 2023.

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds

Recent Sales of Unregistered Equity Securities

On March 13, 2023, we entered into two convertible note purchase agreements made pursuant to Regulation S of the Securities Act of 1933 relating to the sale of convertible notes, under which the Company issued and sold two convertible promissory notes (the “March 2025 Convertible Notes” or “Notes”) in a principal amount of US$3 million to certain investors. The Notes will mature in two years following the issuance, bearing interest at the rate of 6% compounded interest per annum. At any time after the issuance and before the maturity date, the Notes are convertible into the common shares of the Company. The conversion price is US$1.50 per Common Share, subject to adjustment as set forth in the Notes. Unless previously converted, the Company will repay the outstanding principal amount plus all accrued and unpaid interest on the maturity date. The Notes are unsecured general obligations of the Company.

Issuer Purchase of Equity Securities

None.

Table of Contents

Use of Proceeds of Registered Securities

On August 8, 2022, we closed on our underwritten public offering of 780,000 units at a public offering price of $4.25 per unit (the “IPO”). Each unit issued in the offering consisted of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $4.25. The common stock and warrants were immediately separable and were issued separately. The common stock and warrants began trading on the Nasdaq Capital Market on August 9, 2022, under the symbols “AIMD” and “AIMDW,” respectively. Ainos received gross proceeds of approximately $3.3 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In connection with the offering, the Company effectuated a reverse split of its issued and outstanding common stock at a ratio of 1-for-15. The reverse stock split became effective at 8 p.m., Eastern Time, on August 8, 2022.

As part of its offering Ainos granted its underwriters a 45-day option to purchase up to an additional 117,000 shares of common stock and/or up to an additional 117,000 warrants at the public offering price to cover over-allotments. The underwriters partially exercised its option to purchase an additional 117,000 warrants at $0.01/warrant.

Maxim Group LLC acted as sole book-running manager for the offering. Brookline Capital Markets, a division of Arcadia Securities, LLC acted as co-manager for the offering.

The offering was conducted pursuant to the Company’s registration statement on Form S-1 (Registration No. 333-264527) that was previously filed with Securities and Exchange Commission (“SEC”), and declared effective on August 8, 2022.

There has been no material change in the use of proceeds from our IPO as described in our final prospectus filed with the SEC pursuant to Rule 424(b)(4) on August 10, 2022.

ITEM 3. Defaults Upon Senior Securities

None

ITEM 4. Mine Safety Disclosures

Not applicable

ITEM 5. Other Information

None

Table of Contents

ITEM 6. Exhibits

EXHIBIT INDEX

FILED WITH

INCORPORATED BY REFERENCE

EXHIBIT

NUMBER

DESCRIPTION

THIS FORM

10-Q

FILING DATE WITH SEC

FORM

EXH #

HYPERLINK TO

FILINGS

3.1(a)

Restated Certificate of Formation of the Company, dated April 15, 2021

4/21/2021

8-K

3.1

Restated Certificate of Formation of the Company, dated April 15, 2021

3.1(b)

Certificate of Amendment to the Restated Certificate of Formation, dated August 8, 2022

8/12/2022

8-K

3.1

Certificate of Amendment, dated August 8 2022

3.2

Amended and Restated Bylaws of the Company, effective September 28, 2022

10/4/2022

8-K

3.2

Amended and Restated Bylaws, effective September 28, 2022

4.1(a)

Form Common Stock Certificate

4/3/2023

10-K

4.1

Form of Common Stock Certificate

4.1(b)

Form of Warrant

8/2/2022

S-1/A

4.1

Form of Warrant

4.1(c)

Form of Warrant Agency Agreement

8/2/2022

S-1/A

4.3

Form of Warrant Agency Agreement

31.1

Certification of Chief Executive Officer Pursuant to Rule 13a- 14(a) / 15d – 14(a)

31.2

Certification of Chief Financial Officer Pursuant to Rule 13a- 14(a) / 15d – 14(a)

32.1

Certification Of Principal Executive Officer Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section 906 Of The Sarbanes-Oxley Act Of 2002

32.2

Certification Of Principal Financial Officer Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section 906 Of The Sarbanes-Oxley Act Of 2002

100

XBRL – Related Documents

101.INS

XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the XBRL document.

101.SCH

XBRL Taxonomy Extension Schema Document

101.CAL

XBRL Taxonomy Extension Calculation Linkbase

101.DEF

XBRL Taxonomy Extension Definition Linkbase

101.LAB

XBRL Taxonomy Extension Label Linkbase

101.PRE

XBRL Taxonomy Extension Presentation Linkbase

104.1

Cover Page Interactive Data File

The exhibits listed in the Exhibit Index are filed or incorporated by reference as part of this filing.

Table of Contents

SIGNATURES

Pursuant to the requirements of Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	AINOS, INC.

Date: August 11, 2023	By:	/s/ Chun-Hsien Tsai
		Chun-Hsien Tsai, Chairman of the Board, President, and
		Chief Executive Officer

Date: August 11, 2023	By:	/s/ Meng-Lin Sung
		Meng-Lin Sung, Chief Financial Officer

EX-31.1 2 aimd_ex311.htm CERTIFICATION aimd_ex311.htm

EXHIBIT 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO RULE 13A- 14(A) / 15D – 14(A)

UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

I, Chun-Hsien Tsai, certify that:

1.	I have reviewed this report on Form 10-Q of Ainos, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the periods covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 11, 2023

/s/ Chun-Hsien Tsai

Chun-Hsien Tsai, Principal Executive Officer

(Chairman of the Board, President, and Chief Executive Officer)

EX-31.2 3 aimd_ex312.htm CERTIFICATION aimd_ex312.htm

EXHIBIT 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO RULE 13A- 14(A) / 15D – 14(A)

UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

I, Meng-Lin Sung, certify that:

1.

I have reviewed this report on Form 10-Q of Ainos, Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement of material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the periods covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 11, 2023

/s/ Meng-Lin Sung

Meng-Lin Sung, Principal Financial Officer

(Chief Financial Officer)

EX-32.1 4 aimd_ex321.htm CERTIFICATION aimd_ex321.htm

EXHIBIT 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Ainos, Inc. on Form 10-Q for the period ended June 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned, in the capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

1.

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

AINOS, INC.

Date: August 11, 2023

By:

/s/ Chun-Hsien Tsai

Chun-Hsien Tsai, Principal Executive Officer

(Chairman of the Board, President, and Chief Executive Officer)

EX-32.2 5 aimd_ex322.htm CERTIFICATION aimd_ex322.htm

EXHIBIT 32.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

AINOS, INC.

Date: August 11, 2023

By:

/s/ Meng-Lin Sung

Meng-Lin Sung, Principal Financial Officer

(Chief Financial Officer)

EX-101.SCH 6 aimd-20230630.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 000002 - Statement - Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 000003 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 000004 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000005 - Statement - Condensed Statements of Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000006 - Statement - Condensed Statements of Stockholders Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000007 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000008 - Disclosure - Description of Business link:presentationLink link:calculationLink link:definitionLink 000009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 000010 - Disclosure - Cash and Cash Equivalents link:presentationLink link:calculationLink link:definitionLink 000011 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 000012 - Disclosure - Convertible Notes Payable and Other Notes Payable link:presentationLink link:calculationLink link:definitionLink 000013 - Disclosure - Stockholders Equity link:presentationLink link:calculationLink link:definitionLink 000014 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 000015 - Disclosure - ShareBased Compensation link:presentationLink link:calculationLink link:definitionLink 000016 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 000017 - Disclosure - Net Loss per Common Share link:presentationLink link:calculationLink link:definitionLink 000018 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 000019 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 000020 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 000021 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 000022 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 000023 - Disclosure - Convertible Notes Payable and Other Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 000024 - Disclosure - Stockholders Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 000025 - Disclosure - ShareBased Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 000026 - Disclosure - Net Loss per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 000027 - Disclosure - Description of Business (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000028 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000029 - Disclosure - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 000030 - Disclosure - Inventory (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000031 - Disclosure - Convertible Notes Payable and Other Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 000032 - Disclosure - Convertible Notes Payable and Other Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000033 - Disclosure - Stockholders Equity (Details) link:presentationLink link:calculationLink link:definitionLink 000034 - Disclosure - Stockholders Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000035 - Disclosure - ShareBased Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 000036 - Disclosure - ShareBased Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000037 - Disclosure - Net Loss per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 000038 - Disclosure - Net Loss per Common Share (Details 1) link:presentationLink link:calculationLink link:definitionLink 000039 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 7 aimd-20230630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Current Fiscal Year End Date Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Document Period End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Common Stock Shares Outstanding Document Quarterly Report Document Transition Report Entity File Number Entity Incorporation State Country Code Entity Tax Identification Number Entity Interactive Data Current Entity Address Address Line 1 Entity Address Address Line 2 Security 12b Title Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Trading Symbol Security Exchange Name Entity Address City Or Town Class of Stock [Axis] Common Stock And Share [Member] Warrants To Purchase Common Stock [Member] Condensed Balance Sheets Cash and cash equivalents Accounts receivable (including amounts of related party of nil and $177,595 as of June 30, 2023 and December 31,2022, respectively) Inventory, net Other current assets Total current assets [Assets, Current] Intangible assets, net Property and equipment, net Other assets Total assets [Assets] Convertible notes payable, related party Other notes payable, related party Accrued expenses and others current liabilities Total current liabilities [Liabilities, Current] Convertible notes payable (including amounts of related party of $1,500,000 and nil as of June 30, 2023 and December 31, 2022, respectively) Other long-term liabilities Total liabilities [Liabilities] Commitments and contingencies Stockholders' equity: Preferred stock, $0.01 par value; 10,000,000 shares authorized; none issued Common stock, $0.01 par value; 300,000,000 shares authorized as of June 30, 2023 and December 31, 2022, 20,292,624 and 20,011,602 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively Additional paid-in capital Accumulated deficit Translation adjustment Total stockholders' equity [Stockholders' Equity Attributable to Parent] Total liabilities and stockholders' equity [Liabilities and Equity] Preferred stock, par value (in dollars per share) Preferred stock, par value (in dollars per share)B2 Accounts receivable Common stock, par value (in dollars per share) Common stock, shares authorized (in shares) Common stock, shares issued (in shares) Common stock, shares outstanding (in shares) Convertible notes payable Condensed Statements of Operations (Unaudited) Revenues Cost of revenues [Cost of Revenue] Gross (loss) profit [Gross Profit] Operating expenses: Research and development expenses Selling, general and administrative expenses Total operating expenses [Operating Expenses] Loss from operations [Operating Income (Loss)] Non-operating income (expenses), net: Interest expense Other income, net Total non-operating expenses, net [Interest Income (Expense), Nonoperating, Net] Net loss before income taxes Provision for income taxes Net loss [Net Income (Loss) Attributable to Parent] Net loss per common share - basic and diluted Weighted-average shares used in computing net loss per common share-basic and diluted Condensed Statements of Comprehensive Loss (Unaudited) Net loss Other comprehensive loss: Translation adjustment [Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax] Comprehensive loss [Comprehensive Income (Loss), Net of Tax, Attributable to Parent] Condensed Statements of Stockholders Equity (Unaudited) Statement [Table] Statement [Line Items] Equity Components [Axis] Common Stock Preferred Stock Additional Paid-In Capital Retained Earnings (Accumulated Deficit) Accumulated other comprehensive loss Balance, shares [Shares, Issued] Balance, amount Share-based compensation Net loss Translation adjustment [Translation adjustment] Issuance of stock in exchange of vehicle, shares Issuance of stock in exchange of vehicle, amount Conversion of convertible notes payable to common stock, shares Conversion of convertible notes payable to common stock, amount Issuance of stock to settle vested RSUs, shares Issuance of stock to settle vested RSUs, amount Balance, shares Balance, amount Condensed Statements of Cash Flows (Unaudited) Cash flows from operating activities: Net loss [Net Income (Loss), Including Portion Attributable to Noncontrolling Interest] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Loss on inventory write-downs Share-based compensation expense Changes in operating assets and liabilities: Accounts receivable [Increase (Decrease) in Accounts Receivable] Inventory [Increase (Decrease) in Inventories] Other current assets [Increase (Decrease) in Other Current Assets] Accrued expenses and other current and long-term liabilities Operating lease liabilities [Repayments of Debt and Lease Obligation] Contract liabilities Net cash used in operating activities [Net Cash Provided by (Used in) Operating Activities] Cash flows from investing activities: Purchase of property and equipment Net cash used in investing activities [Net Cash Provided by (Used in) Investing Activities] Cash flows from financing activities Proceeds from convertible notes payable Proceeds from convertible notes payable, related party Proceeds from other notes payable, related party Repayments of convertible notes payable, related party [Repayments of Convertible Debt] Repayments of other notes payable, related party [Repayments of Notes Payable] Net cash provided by financing activities [Net Cash Provided by (Used in) Financing Activities] Effect from foreign currency exchange Net (decrease) increase in cash and cash equivalents [Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect] Cash and cash equivalents at beginning of period [Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents] Cash and cash equivalents at end of period Supplemental cash flow information: Cash paid for interest Noncash financing and investing activities Purchase of equipment and intangible assets by issuing convertible notes payable to a related party Conversion of convertible notes payable to common stock and accrued interest waived by convertible note holders Issuance of common stock in exchange of vehicle Payable for purchase of equipment Description of Business Description of Business Business Description and Basis of Presentation [Text Block] Summary of Significant Accounting Policies Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Cash and Cash Equivalents Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Inventory Inventory [Inventory] Convertible Notes Payable and Other Notes Payable Convertible Notes Payable and Other Notes Payable Debt Disclosure [Text Block] Stockholders Equity Stockholders' Equity Revenue Revenue Deferred Revenue Disclosure [Text Block] ShareBased Compensation Share-Based Compensation Income Taxes Income Taxes Income Tax Disclosure [Text Block] Net Loss per Common Share Net Loss per Common Share [Net Loss per Common Share] Related Party Transactions Related Party Transactions Related Party Transactions Disclosure [Text Block] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Subsequent Events Subsequent Events Subsequent Events [Text Block] Basis of Presentation EX-101.CAL 8 aimd-20230630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 9 aimd-20230630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 10 aimd-20230630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	6 Months Ended
Cover - shares	Jun. 30, 2023	Aug. 11, 2023
Document Information Line Items
Entity Registrant Name	AINOS, INC.
Entity Central Index Key	0001014763
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Jun. 30, 2023
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2023
Entity Common Stock Shares Outstanding		20,292,624
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	0-20791
Entity Incorporation State Country Code	TX
Entity Tax Identification Number	75-1974352
Entity Interactive Data Current	Yes
Entity Address Address Line 1	8880 Rio San Diego Drive
Entity Address Address Line 2	Ste. 800
Entity Address State Or Province	CA
Entity Address Postal Zip Code	92108
City Area Code	858
Local Phone Number	869-2986
Entity Address City Or Town	San Diego
Common Stock And Share [Member]
Document Information Line Items
Security 12b Title	Common Stock, par value $0.01 per share
Trading Symbol	AIMD
Security Exchange Name	NASDAQ
Warrants To Purchase Common Stock [Member]
Document Information Line Items
Security 12b Title	Warrants to purchase Common Stock
Trading Symbol	AIMDW
Security Exchange Name	NASDAQ

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Condensed Balance Sheets
Cash and cash equivalents	$ 1,360,970	$ 1,853,362
Accounts receivable (including amounts of related party of nil and $177,595 as of June 30, 2023 and December 31,2022, respectively)	9,385	201,546
Inventory, net	528,114	595,222
Other current assets	241,230	195,787
Total current assets	2,139,699	2,845,917
Intangible assets, net	30,564,203	32,806,738
Property and equipment, net	1,269,331	1,375,676
Other assets	73,169	80,683
Total assets	34,046,402	37,109,014
Convertible notes payable, related party	0	376,526
Other notes payable, related party	684,000	884,000
Accrued expenses and others current liabilities	429,503	1,212,386
Total current liabilities	1,113,503	2,472,912
Convertible notes payable (including amounts of related party of $1,500,000 and nil as of June 30, 2023 and December 31, 2022, respectively)	2,500,000	0
Other long-term liabilities	37,562	8,096
Total liabilities	3,651,065	2,481,008
Preferred stock, $0.01 par value; 10,000,000 shares authorized; none issued
Common stock, $0.01 par value; 300,000,000 shares authorized as of June 30, 2023 and December 31, 2022, 20,292,624 and 20,011,602 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively	202,926	200,116
Additional paid-in capital	59,423,678	58,745,149
Accumulated deficit	(28,985,808)	(24,115,606)
Translation adjustment	(245,459)	(201,653)
Total stockholders' equity	30,395,337	34,628,006
Total liabilities and stockholders' equity	$ 34,046,402	$ 37,109,014

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Condensed Balance Sheets
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, par value (in dollars per share)B2	10,000,000	10,000,000
Accounts receivable	$ 177,595	$ 177,595
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	300,000,000	300,000,000
Common stock, shares issued (in shares)	20,292,624	20,292,624
Common stock, shares outstanding (in shares)	20,011,602	20,011,602
Convertible notes payable	$ 1,500,000	$ 1,500,000

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Condensed Statements of Operations (Unaudited)
Revenues	$ 28,555	$ 636,627	$ 77,719	$ 723,828
Cost of revenues	(55,817)	(318,963)	(156,665)	(360,042)
Gross (loss) profit	(27,262)	317,664	(78,946)	363,786
Operating expenses:
Research and development expenses	1,671,187	1,634,856	3,370,070	3,212,310
Selling, general and administrative expenses	618,149	627,104	1,380,614	1,178,834
Total operating expenses	2,289,336	2,261,960	4,750,684	4,391,144
Loss from operations	(2,316,598)	(1,944,296)	(4,829,630)	(4,027,358)
Non-operating income (expenses), net:
Interest expense	(40,311)	(18,796)	(49,585)	(35,483)
Other income, net	7,182	9,060	9,013	8,914
Total non-operating expenses, net	(33,129)	(9,736)	(40,572)	(26,569)
Net loss before income taxes	(2,349,727)	(1,954,032)	(4,870,202)	(4,053,927)
Provision for income taxes	0	0	0	0
Net loss	$ (2,349,727)	$ (1,954,032)	$ (4,870,202)	$ (4,053,927)
Net loss per common share - basic and diluted	$ (0.12)	$ (0.20)	$ (0.24)	$ (0.42)
Weighted-average shares used in computing net loss per common share-basic and diluted	20,095,705	9,625,133	20,053,886	9,625,133

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Condensed Statements of Comprehensive Loss (Unaudited)
Net loss	$ (2,349,727)	$ (1,954,032)	$ (4,870,202)	$ (4,053,927)
Other comprehensive loss:
Translation adjustment	(53,867)	(165,687)	(43,806)	(223,746)
Comprehensive loss	$ (2,403,594)	$ (2,119,719)	$ (4,914,008)	$ (4,277,673)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed Statements of Stockholders Equity (Unaudited) - USD ($)	Total	Common Stock	Preferred Stock	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)	Accumulated other comprehensive loss
Balance, shares at Dec. 31, 2021		9,625,133
Balance, amount at Dec. 31, 2021	$ 10,197,107	$ 96,251	$ 0	$ 20,203,972	$ (10,108,916)	$ 5,800
Share-based compensation	86,886	0	0	86,886	0	0
Net loss	(4,053,927)	$ 0	0	0	(4,053,927)	0
Translation adjustment	(223,746)		0	0	0	(223,746)
Balance, shares at Jun. 30, 2022		9,625,133
Balance, amount at Jun. 30, 2022	6,006,320	$ 96,251	0	20,290,858	(14,162,843)	(217,946)
Balance, shares at Mar. 31, 2022		9,625,133
Balance, amount at Mar. 31, 2022	8,082,596	$ 96,251	0	20,247,415	(12,208,811)	(52,259)
Share-based compensation	43,443	0	0	43,443	0	0
Net loss	(1,954,032)	0	0	0	(1,954,032)	0
Translation adjustment	(165,687)	$ 0	0	0	0	(165,687)
Balance, shares at Jun. 30, 2022		9,625,133
Balance, amount at Jun. 30, 2022	6,006,320	$ 96,251	0	20,290,858	(14,162,843)	(217,946)
Balance, shares at Dec. 31, 2022		20,011,602
Balance, amount at Dec. 31, 2022	34,628,006	$ 200,116	0	58,745,149	(24,115,606)	(201,653)
Share-based compensation	357,991	0	0	357,991	0	0
Net loss	(4,870,202)	0	0	0	(4,870,202)	0
Translation adjustment	(43,806)	$ 0	0	0	0	(43,806)
Issuance of stock in exchange of vehicle, shares		61,157
Issuance of stock in exchange of vehicle, amount	48,559	$ 612	0	47,947	0	0
Conversion of convertible notes payable to common stock, shares		93,333
Conversion of convertible notes payable to common stock, amount	274,789	$ 933	0	273,856	0	0
Issuance of stock to settle vested RSUs, shares		126,532
Issuance of stock to settle vested RSUs, amount	0	$ 1,265	0	(1,265)	0	0
Balance, shares at Jun. 30, 2023		20,292,624
Balance, amount at Jun. 30, 2023	30,395,337	$ 202,926	0	59,423,678	(28,985,808)	(245,459)
Balance, shares at Mar. 31, 2023		20,011,602
Balance, amount at Mar. 31, 2023	32,338,424	$ 200,116	0	58,965,981	(26,636,081)	(191,592)
Share-based compensation	137,159	0	0	137,159	0	0
Net loss	(2,349,727)	0	0	0	(2,349,727)	0
Translation adjustment	(53,867)	$ 0	0	0	0	(53,867)
Issuance of stock in exchange of vehicle, shares		61,157
Issuance of stock in exchange of vehicle, amount	48,559	$ 612	0	47,947	0	0
Conversion of convertible notes payable to common stock, shares		93,333
Conversion of convertible notes payable to common stock, amount	274,789	$ 933	0	273,856	0	0
Issuance of stock to settle vested RSUs, shares		126,532
Issuance of stock to settle vested RSUs, amount	0	$ 1,265	0	(1,265)	0	0
Balance, shares at Jun. 30, 2023		20,292,624
Balance, amount at Jun. 30, 2023	$ 30,395,337	$ 202,926	$ 0	$ 59,423,678	$ (28,985,808)	$ (245,459)

XML 17 R7.htm IDEA: XBRL DOCUMENT

Condensed Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities:
Net loss	$ 4,870,202	$ 4,053,927
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,423,274	2,378,835
Loss on inventory write-downs	57,474	0
Share-based compensation expense	357,991	86,886
Changes in operating assets and liabilities:
Accounts receivable	192,161	(29,881)
Inventory	10,814	670,507
Other current assets	55,990	775,909
Accrued expenses and other current and long-term liabilities	(684,372)	838,484
Operating lease liabilities	(9,603)	(10,125)
Contract liabilities	0	606,866
Net cash used in operating activities	(2,578,453)	(1,629,278)
Cash flows from investing activities:
Purchase of property and equipment	71,262	424,557
Net cash used in investing activities	(71,262)	(424,557)
Cash flows from financing activities
Proceeds from convertible notes payable	1,000,000	850,000
Proceeds from convertible notes payable, related party	1,500,000	550,000
Proceeds from other notes payable, related party	0	800,000
Repayments of convertible notes payable, related party	(114,026)	0
Repayments of other notes payable, related party	(200,000)	0
Net cash provided by financing activities	2,185,974	2,200,000
Effect from foreign currency exchange	(28,651)	(143,787)
Net (decrease) increase in cash and cash equivalents	(492,392)	2,378
Cash and cash equivalents at beginning of period	1,853,362	1,751,499
Cash and cash equivalents at end of period	1,360,970	1,753,877
Supplemental cash flow information:
Cash paid for interest	3,122	0
Noncash financing and investing activities
Purchase of equipment and intangible assets by issuing convertible notes payable to a related party	0	26,000,000
Conversion of convertible notes payable to common stock and accrued interest waived by convertible note holders	274,789	0
Issuance of common stock in exchange of vehicle	48,559	0
Payable for purchase of equipment	$ 0	$ 117,185

XML 18 R8.htm IDEA: XBRL DOCUMENT

Description of Business

6 Months Ended

Jun. 30, 2023

Description of Business

Description of Business

1. Description of Business

Organization and Business

Underwritten Public Offering

The Company filed a Certificate of Amendment to its Restated Certificate of Formation with the Secretary of State of Texas on August 8, 2022 that effectuated the Reverse Stock Split.

XML 19 R9.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2023

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Basis of Presentation

There have been no material changes to the Company’s significant accounting policies as described in the audited financial statements as of December 31, 2022.

Use of Estimates

Liquidity

Segments

Impairment of Intangible Assets

Recent Accounting Pronouncements Adopted

Accounting Standards Issued but Not Yet Adopted

No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s financial statements.

XML 20 R10.htm IDEA: XBRL DOCUMENT

Cash and Cash Equivalents

6 Months Ended

Jun. 30, 2023

Cash and Cash Equivalents

Cash and Cash Equivalents

3. Cash and Cash Equivalents

XML 21 R11.htm IDEA: XBRL DOCUMENT

Inventory

6 Months Ended

Jun. 30, 2023

Inventory

Inventory

4. Inventory

Inventory stated at cost, net of reserve, consisted of the following:

	June 30,		December 31,
	2023		2022
Raw materials	$	354,175	$	393,253
Work in process		67,736		111,119
Finished goods		106,203		90,850
Total	$	528,114	$	595,222

XML 22 R12.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable and Other Notes Payable

6 Months Ended

Jun. 30, 2023

Convertible Notes Payable and Other Notes Payable

Convertible Notes Payable and Other Notes Payable

5. Convertible Notes Payable and Other Notes Payable

As of June 30, 2023 and December 31, 2022, the respective notes payable was as follows:

	June 30, 2023		December 31, 2022
Convertible notes payable, related party – current	$	-	$	376,526
Other notes payable, related party - current		684,000		884,000
March 2025 Convertible Notes, related party - noncurrent		1,500,000		-
March 2025 Convertible Notes - noncurrent		1,000,000		-
	$	3,184,000	$	1,260,526

March 2025 Convertible Notes

Convertible Note Issued to ASE Test, Inc. (the “ASE Note”)

Convertible Note Issued to Li-Kuo Lee (the “Lee Note”)

The Company issued a convertible note to an unrelated party, Li-Kuo Lee in exchange of $1,000,000 in cash. As of June 30, 2023, the Company received the full amount of the payment.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

XML 23 R13.htm IDEA: XBRL DOCUMENT

Stockholders Equity

6 Months Ended

Jun. 30, 2023

Stockholders Equity

Stockholders' Equity

6. Stockholders’ Equity

Common Stock

Warrants

As of June 30, 2023 and December 31, 2022, warrants issued and outstanding in connection with financing are summarized as below:

	June 30,		December 31,
(In number of shares)	2023		2022
Public warrant with exercise price of $4.25		897,000		897,000
Private warrant with exercise price of $4.675		39,000		39,000
Total		936,000		936,000

In addition, the warrant issued by the Company to i2China in 2020 in exchange for consulting services is accounted for under ASC 718, Compensation - Stock Compensation. Refer to Note 8.

As of June 30, 2023, none of the warrants have been exercised nor have expired.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

XML 24 R14.htm IDEA: XBRL DOCUMENT

Revenue

6 Months Ended

Jun. 30, 2023

Revenue

Revenue

7. Revenue

XML 25 R15.htm IDEA: XBRL DOCUMENT

ShareBased Compensation

6 Months Ended

Jun. 30, 2023

ShareBased Compensation

Share-Based Compensation

8. Share-Based Compensation

2023 Stock Incentive Plan

2021 Stock Incentive Plan

2021 Employee Stock Purchase Plan

Restricted Stock Units (“RSUs”)

	Number of Share			Weighted-Average Grant Date Fair Value Per Share
Unvested balance at December 31, 2022		800,000		$	2.42
RSUs granted		-		$	-
RSUs vested*		(29,332	)	$	11.10
RSUs forfeited		(38,000	)	$	1.43
Unvested balance at March 31, 2023		732,668		$	2.12
RSUs granted		-		$	-
RSUs vested**		(101,100	)	$	1.34
RSUs forfeited		(34,850	)	$	1.27
Unvested balance at June 30, 2023		596,718		$	2.30

* The common stock underlying the vested RSUs was delivered to grantees during the three months ended June 30, 2023.

** 3,900 shares of vested RSUs have not been settled by issuance of common shares to grantees as of June 30, 2023.

Stock Options and Warrants

Share-Based Compensation Expense

XML 26 R16.htm IDEA: XBRL DOCUMENT

Income Taxes

6 Months Ended

Jun. 30, 2023

Income Taxes

Income Taxes

9. Income Taxes

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 27 R17.htm IDEA: XBRL DOCUMENT

Net Loss per Common Share

6 Months Ended

Jun. 30, 2023

Net Loss per Common Share

Net Loss per Common Share

10. Net Loss per Common Share

The following table sets forth the computation of the basic and diluted net loss per share attributable to common stockholders:

	Three Months Ended June 30,						Six Months Ended June 30,
	2023			2022			2023			2022
Net loss attributable to common stockholders, basic and diluted	$	(2,349,727	)	$	(1,954,032	)	$	(4,870,202	)	$	(4,053,927	)
Weighted-average number of shares used in computing net loss per share attributable to common stockholders, basic and diluted		20,095,705			9,625,133			20,053,886			9,625,133
Net loss per share attributable to common stockholders, basic and diluted	$	(0.12	)	$	(0.20	)	$	(0.24	)	$	(0.42	)

The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding because they would be anti-dilutive:

	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Option and RSUs to purchase common stock		633,384		36,666		633,384		36,666
Warrants to purchase common stock		966,174		30,174		966,174		30,174
Convertible note to purchase common stock		1,666,667		9,197,405		1,666,667		9,197,405
Total potential shares		3,266,225		9,264,245		3,266,225		9,264,245

XML 28 R18.htm IDEA: XBRL DOCUMENT

Related Party Transactions

6 Months Ended

Jun. 30, 2023

Related Party Transactions

Related Party Transactions

11. Related Party Transactions

The following is a summary of related party transactions that met our disclosure threshold:

Asset Purchase Agreement

Working Capital Advances

Purchase and Sales

Ainos COVID-19 Test Kits Sales and Marketing Agreement with Ainos KY

COVID-19 Antigen Rapid Test Kits Sales

Product Co-development Agreement

Miscellaneous

XML 29 R19.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

6 Months Ended

Jun. 30, 2023

Commitments and contingencies

Commitments and Contingencies

12. Commitments and Contingencies

XML 30 R20.htm IDEA: XBRL DOCUMENT

Subsequent Events

6 Months Ended

Jun. 30, 2023

Subsequent Events

Subsequent Events

13. Subsequent Events

XML 31 R21.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2023
Summary of Significant Accounting Policies
Basis of Presentation	The accompanying condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (the “GAAP”) and pursuant to the accounting disclosure rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed financial statements should be read in conjunction with the financial statements and notes included in the Company’s audited financial statements as of and for the year ended December 31, 2022 contained in the Annual Report on Form 10-K filed with the SEC on April 3, 2023. In the opinion of management, the accompanying condensed financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods. The results for the three and six months ended June 30, 2023 are not necessarily indicative of the results to be expected for any subsequent quarter, the year ending December 31, 2023, or any other period. There have been no material changes to the Company’s significant accounting policies as described in the audited financial statements as of December 31, 2022.
Use of Estimates	The preparation of condensed financial statements in conformity with GAAP requires management to make certain estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and disclosures as of the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates on various factors, including historical experience, and on various other assumptions that are believed to be reasonable under the circumstances, when these carrying values are not readily available from other sources. Significant items subject to estimates and assumptions include useful lives of property and equipment, valuation of stock option and warrants, and impairment testing of intangible assets. Actual results may differ from these estimates.
Liquidity	As of June 30, 2023, the Company had cash and cash equivalents of $1,360,970. The Company plans to finance its operations and development needs with its existing cash and cash equivalents, additional equity and/or debt financing arrangements, and expected revenue primarily from the sale of VELDONA Pet cytoprotein supplements to support the Company’s clinical trial activities, largely in connection with Ainos Flora and VELDONA therapeutics for humans. There can be no assurance that the Company will be able to obtain additional financing on terms acceptable to the Company, on a timely basis, or at all. If the Company is not able to obtain sufficient funds on acceptable terms when needed, the Company’s business, results of operations, and financial condition could be materially adversely impacted. For the six months ended June 30, 2023, the Company generated a net loss of $4,870,202. The Company expects to continue incurring development expenses for the next twelve months as the Company advances Ainos Flora and VELDONA therapeutics for humans through clinical development until regulatory approval is received and the sales and marketing of the products are authorized. The financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net operating losses in every year since inception and has an accumulated deficit as of June 30, 2023 of $28,985,808 and expects to incur additional losses and negative operating cash flows for at least the next twelve months. The Company’s ability to meet its obligations is dependent upon its ability to generate sufficient cash flows from operations and future financing transactions. Although management expects the Company will continue as a going concern, there is no assurance that management’s plans will be successful since the availability and amount of such funding is not certain. Accordingly, substantial doubt exists about the Company’s ability to continue as a going concern for at least one year from the issuance of these financial statements. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.
Segments	Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the chief operating decision maker (the “CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s Chief Executive Officer is the Company’s CODM. The CODM reviews financial information prepared on the basis of accounting policy disclosed in its annual financial statement for purposes of making operating decisions, allocating resources, and evaluating financial performance of the Company. As such, the Company has determined that it operates as one operating segment.
Impairment of Intangible Assets	The Company reviews its definite-lived intangibles and other long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be fully recoverable. When such events occur, management determines whether there has been impairment by comparing the anticipated undiscounted future net cash flows to the carrying value of the asset or asset group. If impairment exists, the assets are written down to their estimated fair value. No impairment of definite-lived intangible and long-lived assets was recorded for the three and six months ended June 30, 2023 and 2022.
Recent Accounting Pronouncements Adopted	On January 1, 2023, the Company adopted Accounting Standards Update (the “ASU”) 2016-13 (the “ASU 2016-13”), Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which the Financial Accounting Standards Board (the “FASB”) issued in June 2016. The new standard changes the accounting for credit losses for financial assets and certain other instruments, including trade receivables and contract assets that are not measured at fair value through net income. Under legacy standards, the Company recognizes an impairment of receivables when it was probable that a loss had been incurred. Under the new standard pursuant to ASU 2016-13, the Company is required to recognize estimated credit losses expected to occur over the estimated life or remaining contractual life of an asset (which includes losses that may be incurred in future periods) using a broader range of information including reasonable and supportable forecasts about future economic conditions. The guidance is effective for smaller reporting companies (the “SRC”) as defined by the SEC for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years with early adoption permitted. The Company’s adoption of this new guidance did not have a material impact on the Company’s financial statements and related disclosure. On January 1, 2023, the Company early adopted ASU 2020-06 (the “ASU 2020-06”), Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 as issued by FASB in August 2020 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for SRC’s fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. The Company’s early adoption of this new guidance did not have a material impact on its financial statements and related disclosures.
Accounting Standards Issued but Not Yet Adopted	No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s financial statements.

XML 32 R22.htm IDEA: XBRL DOCUMENT

Inventory (Tables)

6 Months Ended

Jun. 30, 2023

Inventory

Inventories

	June 30,		December 31,
	2023		2022
Raw materials	$	354,175	$	393,253
Work in process		67,736		111,119
Finished goods		106,203		90,850
Total	$	528,114	$	595,222

XML 33 R23.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable and Other Notes Payable (Tables)

6 Months Ended

Jun. 30, 2023

Convertible Notes Payable and Other Notes Payable

Convertible Notes Payable and Other Notes Payable

	June 30, 2023		December 31, 2022
Convertible notes payable, related party – current	$	-	$	376,526
Other notes payable, related party - current		684,000		884,000
March 2025 Convertible Notes, related party - noncurrent		1,500,000		-
March 2025 Convertible Notes - noncurrent		1,000,000		-
	$	3,184,000	$	1,260,526

XML 34 R24.htm IDEA: XBRL DOCUMENT

Stockholders Equity (Tables)

6 Months Ended

Jun. 30, 2023

Stockholders Equity

Warrants

	June 30,		December 31,
(In number of shares)	2023		2022
Public warrant with exercise price of $4.25		897,000		897,000
Private warrant with exercise price of $4.675		39,000		39,000
Total		936,000		936,000

XML 35 R25.htm IDEA: XBRL DOCUMENT

ShareBased Compensation (Tables)

6 Months Ended

Jun. 30, 2023

ShareBased Compensation

Schedule of Restricted Stock Units

	Number of Share			Weighted-Average Grant Date Fair Value Per Share
Unvested balance at December 31, 2022		800,000		$	2.42
RSUs granted		-		$	-
RSUs vested*		(29,332	)	$	11.10
RSUs forfeited		(38,000	)	$	1.43
Unvested balance at March 31, 2023		732,668		$	2.12
RSUs granted		-		$	-
RSUs vested**		(101,100	)	$	1.34
RSUs forfeited		(34,850	)	$	1.27
Unvested balance at June 30, 2023		596,718		$	2.30

XML 36 R26.htm IDEA: XBRL DOCUMENT

Net Loss per Common Share (Tables)

6 Months Ended

Jun. 30, 2023

Net Loss per Common Share

Schedule of basic and diluted net loss per share

	Three Months Ended June 30,						Six Months Ended June 30,
	2023			2022			2023			2022
Net loss attributable to common stockholders, basic and diluted	$	(2,349,727	)	$	(1,954,032	)	$	(4,870,202	)	$	(4,053,927	)
Weighted-average number of shares used in computing net loss per share attributable to common stockholders, basic and diluted		20,095,705			9,625,133			20,053,886			9,625,133
Net loss per share attributable to common stockholders, basic and diluted	$	(0.12	)	$	(0.20	)	$	(0.24	)	$	(0.42	)

Schedule of computations of diluted weighted average shares outstanding

	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Option and RSUs to purchase common stock		633,384		36,666		633,384		36,666
Warrants to purchase common stock		966,174		30,174		966,174		30,174
Convertible note to purchase common stock		1,666,667		9,197,405		1,666,667		9,197,405
Total potential shares		3,266,225		9,264,245		3,266,225		9,264,245

XML 37 R27.htm IDEA: XBRL DOCUMENT

Description of Business (Details Narrative)	6 Months Ended
Description of Business (Details Narrative)	Jun. 30, 2023 $ / shares shares
Description of Business
Public offering price	$ 4.25
Exercise price of share	$ 4.25
Stock split description	1-for-15
Aggregate public offering \| shares	780,000

XML 38 R28.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Summary of Significant Accounting Policies
Cash and cash equivalents	$ 1,360,970		$ 1,360,970
Net loss	(2,349,727)	$ (1,954,032)	(4,870,202)	$ (4,053,927)
Accumulated deficit	$ (28,985,808)		$ (28,985,808)		$ (24,115,606)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

XML 39 R29.htm IDEA: XBRL DOCUMENT

Inventory (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Inventory
Raw materials	$ 354,175	$ 393,253
Work in process	67,736	111,119
Finished goods	106,203	90,850
Total	$ 528,114	$ 595,222

XML 40 R30.htm IDEA: XBRL DOCUMENT

Inventory (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended
Inventory (Details Narrative) - USD ($)	Jun. 30, 2023	Jun. 30, 2023	Jun. 30, 2022
Inventory
Estimated net realizable values	$ 14,694	$ 57,474	$ 0

XML 41 R31.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable and Other Notes Payable (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022	Jan. 30, 2022
Convertible notes payable, related party - current	$ 0	$ 376,526
Other notes payable, related party - current	684,000	884,000
Total Convertible and other notes payable	3,184,000	1,260,526	$ 26,000,000
March 2025 Convertible Notes [Member]
Total Convertible and other notes payable	1,000,000	0
Convertible Notes, related party - noncurrent	$ 1,500,000	$ 0

XML 42 R32.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable and Other Notes Payable (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Aug. 31, 2023	Jul. 31, 2023	Dec. 31, 2022	Jan. 30, 2022
Total Convertible and other notes payable	$ 3,184,000		$ 3,184,000				$ 1,260,526	$ 26,000,000
Conversion price description			1-for-15
Common stock	20,292,624		20,292,624				20,292,624
Chen [Member]
Conversion price description			price of $2.52 or $2.81 per share
Interest rate description			rate of 0.75% or 0.65%.
Note paid	$ 114,026
Unrelated parties	$ 262,500
Common stock	93,333		93,333
Ainos KY [Member]
Note paid			$ 200,000
Interest rate	1.85%		1.85%
Working capital	$ 800,000		$ 800,000
Notes payable	84,000		84,000
Ainos KY [Member] \| Subsequent Event [Member]
Convertible note payable						$ 300,000
Accrued interest and the remaining principal amount						$ 300,000
i2China [Member] \| Subsequent Event [Member]
Convertible note payable					$ 42,000
Accrued interest and the remaining principal amount					$ 42,000
Li-Kuo Lee [Member]
Total Convertible and other notes payable	$ 1,000,000		$ 1,000,000
Conversion price	$ 1.50		$ 1.50
Interest rate	6.00%		6.00%
March 2025 Convertible Notes [Member]
Total principal amount			$ 3,000,000
Description of Convertible Note Sale to ASE Test, Inc			ASE Test, Inc., a shareholder of Ainos KY, committed to pay a total aggregate amount of $2,000,000 to the Company in exchange for convertible promissory note(s) in three tranches in the amounts of $1,000,000 (the “First Tranche”), $500,000 (the “Second Tranche”), and $500,000 (the “Third Tranche”) which is conditioned, among other things, on the Company achieving certain business milestones.
Total Convertible and other notes payable	$ 1,000,000		$ 1,000,000				$ 0
Interest expense	37,991	$ 18,602	44,924	$ 34,486
Unpaid accrued interest	64,795		64,795				$ 35,282
Long term liabilities	$ 37,562		$ 37,562

XML 43 R33.htm IDEA: XBRL DOCUMENT

Stockholders Equity (Details) - Warrants [Member] - shares	Jun. 30, 2023	Dec. 31, 2022
Public warrant with exercise price of $4.25	897,000	897,000
Private warrant with exercise price of $4.675	39,000	39,000
Total	936,000	936,000

XML 44 R34.htm IDEA: XBRL DOCUMENT

Stockholders Equity (Details Narrative) - shares	1 Months Ended	6 Months Ended
Stockholders Equity (Details Narrative) - shares	Apr. 26, 2023	Jun. 30, 2023
Conversion of stock	61,157
Common Shares [Member]
Common stock issued and outstanding		20,292,624
Conversion of stock in exchange for vehicle		61,157
Conversion of stock		93,333
Vested RSUs		126,532
Warrants expiring term		of 5 years, expiring on August 8, 2027
Additional stock issued		281,022

XML 45 R35.htm IDEA: XBRL DOCUMENT

ShareBased Compensation (Details) - Restricted Stock Units - $ / shares	3 Months Ended
	Jun. 30, 2023	Mar. 31, 2023
Options Outstanding, Beginning	732,668	800,000
RSUs vested	(101,100)	(29,332)
RSUs forfeited	(34,850)	(38,000)
Options outstanding, Ending	596,718	732,668
Weighted-Average Grant Date Fair Value Per RSU, beginning balance	$ 2.12	$ 2.42
Weighted-Average Grant Date Fair Value Per RSUs granted	0	0
Weighted-Average Grant Date Fair Value Per RSUs vested	1.34	11.10
Weighted-Average Grant Date Fair Value Per RSUs forfeited	1.27	1.43
Weighted-Average Grant Date Fair Value Per RSU, ending balance	$ 2.30	$ 2.12

XML 46 R36.htm IDEA: XBRL DOCUMENT

ShareBased Compensation (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
ShareBased Compensation (Details Narrative) - USD ($)	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Jun. 14, 2023
Issuance of common shares, vested	3,900		3,900
Unrecognized Option Expense	$ 1,439,499		$ 1,439,499
Unrecognized Option Expense Period Of Recognition			1 year 10 months 6 days
Share-based compensation expense	$ 137,159	$ 43,443	$ 357,991	$ 86,886
Warrants to purchase common stock	966,174	30,174	966,174	30,174
Option and RSUs to purchase common stock	633,384	36,666	633,384	36,666
Stock option and Warrants [Member]
Warrants to purchase common stock			30,174
Option and RSUs to purchase common stock			36,666
2023 Stock Incentive Plan
Number Of Shares Of Common Stock Issued					4,355,376

XML 47 R37.htm IDEA: XBRL DOCUMENT

Net Loss per Common Share (Details) - USD ($)	3 Months Ended		6 Months Ended
Net Loss per Common Share (Details) - USD ($)	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Net Loss per Common Share
Net loss attributable to common stockholders, basic and diluted	$ (2,349,727)	$ (1,954,032)	$ (4,870,202)	$ (4,053,927)
Weighted-average number of shares used in computing net loss per share attributable to common stockholders, basic and diluted	20,095,705	9,625,133	20,053,886	9,625,133
Net loss per share attributable to common stockholders, basic and diluted	$ (0.12)	$ (0.20)	$ (0.24)	$ (0.42)

XML 48 R38.htm IDEA: XBRL DOCUMENT

Net Loss per Common Share (Details 1) - shares	3 Months Ended		6 Months Ended
Net Loss per Common Share (Details 1) - shares	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Net Loss per Common Share
Option and RSUs to purchase common stock	633,384	36,666	633,384	36,666
Warrants to purchase common stock	966,174	30,174	966,174	30,174
Convertible note to purchase common stock	1,666,667	9,197,405	1,666,667	9,197,405
Total potential shares	3,266,225	9,264,245	3,266,225	9,264,245

XML 49 R39.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Apr. 26, 2023	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Jan. 30, 2022
Assets purchase agrement		$ 26,000,000		$ 26,000,000
Interest expense incurred		23,031	$ 18,602	26,841	$ 34,486
Unpaid accrued interest expenses		46,712		46,712		$ 35,282
Issuance of common stock	61,157
Market price	$ 48,559
Convertible notes payable		3,184,000		3,184,000		1,260,526	$ 26,000,000
Development expenses		1,671,187	1,634,856	3,370,070	3,212,310
Mr. Chien-Hsuan Huang [Member]
Development expenses		19,618		39,344
Product Co-development Agreement [Member]
Development expenses		74,733	206,748	152,196	374,170
Deposits from related party		31,071		31,071		31,490
Equipment		1,113,977		1,113,977
Property assets		24,886,023		24,886,023
Accounts payable to related party		25,089		25,089		70,113
Ainos COVID-19 Test Kits Sales and Marketing Agreement with Ainos KY
Totaling		0	483,992	46,635	870,404
Prepayment to related party		90,519		90,519		0
Accounts payable to related party		0		0		24,365
COVID-19 Antigen Rapid Test Kits Sales
Totaling		12,541	$ 401,259	12,541	$ 482,359
Accounts receivable		$ 0		$ 0		$ 177,595

XML 50 aimd_10q_htm.xml IDEA: XBRL DOCUMENT 0001014763 2023-01-01 2023-06-30 0001014763 aimd:COVID19AntigenRapidTestKitsSalesMember 2022-12-31 0001014763 aimd:COVID19AntigenRapidTestKitsSalesMember 2023-06-30 0001014763 aimd:COVID19AntigenRapidTestKitsSalesMember 2022-01-01 2022-06-30 0001014763 aimd:COVID19AntigenRapidTestKitsSalesMember 2022-04-01 2022-06-30 0001014763 aimd:COVID19AntigenRapidTestKitsSalesMember 2023-04-01 2023-06-30 0001014763 aimd:COVID19AntigenRapidTestKitsSalesMember 2023-01-01 2023-06-30 0001014763 aimd:AinosCOVID19TestKitsSalesandMarketinAgreementwithainosKYMember 2022-12-31 0001014763 aimd:AinosCOVID19TestKitsSalesandMarketinAgreementwithainosKYMember 2023-06-30 0001014763 aimd:AinosCOVID19TestKitsSalesandMarketinAgreementwithainosKYMember 2022-01-01 2022-06-30 0001014763 aimd:AinosCOVID19TestKitsSalesandMarketinAgreementwithainosKYMember 2022-04-01 2022-06-30 0001014763 aimd:AinosCOVID19TestKitsSalesandMarketinAgreementwithainosKYMember 2023-04-01 2023-06-30 0001014763 aimd:AinosCOVID19TestKitsSalesandMarketinAgreementwithainosKYMember 2023-01-01 2023-06-30 0001014763 aimd:ProductCoDevelopmentAgreementMember 2023-06-30 0001014763 aimd:ProductCoDevelopmentAgreementMember 2022-12-31 0001014763 aimd:ProductCoDevelopmentAgreementMember 2022-01-01 2022-06-30 0001014763 aimd:ProductCoDevelopmentAgreementMember 2022-04-01 2022-06-30 0001014763 aimd:ProductCoDevelopmentAgreementMember 2023-04-01 2023-06-30 0001014763 aimd:ProductCoDevelopmentAgreementMember 2023-01-01 2023-06-30 0001014763 aimd:Chien-HsuanHuangMember 2023-01-01 2023-06-30 0001014763 aimd:Chien-HsuanHuangMember 2023-04-01 2023-06-30 0001014763 2022-01-30 0001014763 2023-04-01 2023-04-26 0001014763 aimd:TwoThousandTwentyThreeStockIncentivePlanMember 2023-06-14 0001014763 aimd:StockOptionAndWarrantsMember 2023-01-01 2023-06-30 0001014763 us-gaap:RestrictedStockUnitsRSUMember 2023-06-30 0001014763 us-gaap:RestrictedStockUnitsRSUMember 2023-04-01 2023-06-30 0001014763 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001014763 us-gaap:RestrictedStockUnitsRSUMember 2023-03-31 0001014763 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001014763 aimd:CommonSharesMember 2023-01-01 2023-06-30 0001014763 aimd:CommonSharesMember 2023-06-30 0001014763 aimd:WarrantsMember 2023-06-30 0001014763 aimd:WarrantsMember 2022-12-31 0001014763 aimd:March2025ConvertibleNotesMember 2022-01-01 2022-06-30 0001014763 aimd:March2025ConvertibleNotesMember 2022-04-01 2022-06-30 0001014763 aimd:March2025ConvertibleNotesMember 2023-04-01 2023-06-30 0001014763 aimd:AinosKyMember 2023-06-30 0001014763 aimd:AinosKyMember 2023-01-01 2023-06-30 0001014763 aimd:ChenMember 2023-06-30 0001014763 aimd:ChenMember 2023-04-01 2023-06-30 0001014763 aimd:ChenMember 2023-01-01 2023-06-30 0001014763 aimd:ITwoChinaNoteMember us-gaap:SubsequentEventMember 2023-08-31 0001014763 aimd:AinosKyMember us-gaap:SubsequentEventMember 2023-07-31 0001014763 aimd:LiKuoLeeMember 2023-06-30 0001014763 aimd:March2025ConvertibleNotesMember 2023-01-01 2023-06-30 0001014763 aimd:March2025ConvertibleNotesMember 2022-12-31 0001014763 aimd:March2025ConvertibleNotesMember 2023-06-30 0001014763 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001014763 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001014763 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001014763 aimd:CommonStcksMember 2023-04-01 2023-06-30 0001014763 us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0001014763 2023-03-31 0001014763 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001014763 us-gaap:RetainedEarningsMember 2023-03-31 0001014763 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001014763 us-gaap:PreferredStockMember 2023-03-31 0001014763 aimd:CommonStcksMember 2023-03-31 0001014763 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001014763 us-gaap:RetainedEarningsMember 2023-06-30 0001014763 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001014763 aimd:CommonStcksMember 2023-06-30 0001014763 us-gaap:PreferredStockMember 2023-06-30 0001014763 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-06-30 0001014763 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0001014763 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0001014763 aimd:CommonStcksMember 2023-01-01 2023-06-30 0001014763 us-gaap:PreferredStockMember 2023-01-01 2023-06-30 0001014763 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001014763 us-gaap:RetainedEarningsMember 2022-12-31 0001014763 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001014763 aimd:CommonStcksMember 2022-12-31 0001014763 us-gaap:PreferredStockMember 2022-12-31 0001014763 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001014763 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001014763 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001014763 aimd:CommonStcksMember 2022-04-01 2022-06-30 0001014763 us-gaap:PreferredStockMember 2022-04-01 2022-06-30 0001014763 2022-03-31 0001014763 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001014763 us-gaap:RetainedEarningsMember 2022-03-31 0001014763 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001014763 aimd:CommonStcksMember 2022-03-31 0001014763 us-gaap:PreferredStockMember 2022-03-31 0001014763 2022-06-30 0001014763 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001014763 us-gaap:RetainedEarningsMember 2022-06-30 0001014763 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001014763 aimd:CommonStcksMember 2022-06-30 0001014763 us-gaap:PreferredStockMember 2022-06-30 0001014763 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-06-30 0001014763 us-gaap:RetainedEarningsMember 2022-01-01 2022-06-30 0001014763 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-06-30 0001014763 aimd:CommonStcksMember 2022-01-01 2022-06-30 0001014763 us-gaap:PreferredStockMember 2022-01-01 2022-06-30 0001014763 2021-12-31 0001014763 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001014763 us-gaap:RetainedEarningsMember 2021-12-31 0001014763 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001014763 aimd:CommonStcksMember 2021-12-31 0001014763 us-gaap:PreferredStockMember 2021-12-31 0001014763 2022-01-01 2022-06-30 0001014763 2022-04-01 2022-06-30 0001014763 2023-04-01 2023-06-30 0001014763 2022-12-31 0001014763 2023-06-30 0001014763 2023-08-11 0001014763 aimd:CommonStockAndShareMember 2023-01-01 2023-06-30 0001014763 aimd:WarrantsToPurchaseCommonStockMember 2023-01-01 2023-06-30 iso4217:USD shares iso4217:USD shares pure 0001014763 false --12-31 Q2 2023

0.01

10000000

177595 177595

0.01

300000000

20292624

20011602

1500000 1500000 0 0 0

0 10-Q true 2023-06-30 false 0-20791 AINOS, INC. TX 75-1974352 8880 Rio San Diego Drive Ste. 800 San Diego CA 92108 858 869-2986 Common Stock, par value $0.01 per share AIMD NASDAQ Warrants to purchase Common Stock AIMDW NASDAQ Yes Yes Non-accelerated Filer true false false 20292624

1360970

1853362

9385

201546

528114

595222

241230

195787

2139699

2845917

30564203 32806738

1269331

1375676

73169

80683

34046402

37109014

376526

684000 884000

429503

1212386

1113503

2472912

2500000 0

37562

8096

3651065

2481008

202926

200116

59423678

58745149

-28985808

-24115606

-245459 -201653

30395337

34628006

34046402

37109014

28555

636627

77719

723828

55817

318963

156665

360042

-27262

317664

-78946

363786

1671187

1634856

3370070

3212310

618149

627104

1380614

1178834

2289336

2261960

4750684

4391144

-2316598

-1944296

-4829630

-4027358

-40311

-18796

-49585

-35483

7182

9060

9013

8914

-33129

-9736

-40572

-26569

-2349727

-1954032

-4870202

-4053927

-2349727

-1954032

-4870202

-4053927

-0.12 -0.20 -0.24 -0.42

20095705

9625133

20053886

9625133

-2349727

-1954032

-4870202

-4053927

53867

165687

43806

223746

-2403594

-2119719

-4914008

-4277673

20011602

200116

58965981

-26636081

-191592

32338424

0 61157 612 47947 0 0 48559 0 93333 933 273856 0 0 274789 0 126532 1265 -1265 0 0 0

137159

-2349727

0 0 0 0 -53867 -53867

20292624

202926

59423678

-28985808

-245459

30395337

9625133

96251

20247415

-12208811

-52259

8082596

43443

-1954032

0 0 0 0 -165687 -165687

9625133

96251

20290858

-14162843

-217946

6006320

20011602

200116

58745149

-24115606

-201653

34628006

0 61157 612 47947 0 0 48559 0 93333 933 273856 0 0 274789 0 126532 1265 -1265 0 0 0

357991

-4870202

0 0 0 0 -43806 -43806

20292624

202926

59423678

-28985808

-245459

30395337

9625133

96251

20203972

-10108916

5800

10197107

86886

-4053927

0 0 0 -223746 -223746

9625133

96251

20290858

-14162843

-217946

6006320

-4870202

-4053927

2423274

2378835

57474

357991

86886

-192161

29881

-10814

-670507

-55990

-775909

-684372

838484

9603

10125

606866

-2578453

-1629278

71262

424557

-71262

-424557

1000000

850000

1500000

550000

800000

114026

200000

2185974

2200000

-28651

-143787

-492392

2378

1853362

1751499

1360970

1753877

3122

26000000

274789 0

48559

117185

1. Description of Business Organization and Business Ainos, Inc. (the “Company”), incorporated in the State of Texas, is a diversified healthcare company focused on the development of novel point-of-care testing (POCT), therapeutics based on very low-dose interferon alpha (VELDONA), and synthetic RNA-driven preventative medicine. Our products include VELDONA clinical-stage human therapeutics, VELDONA Pet cytoprotein supplements, and telehealth-friendly POCTs powered by AI Nose technology platform. The Company’s POCT platforms aim to provide connected, rapid and convenient testing of a broad range of health conditions. Building on its extensive research and development on VELDONA, the Company is focused on commercializing a suite of VELDONA-based products including VELDONA Pet cytoprotein supplements and VELDONA therapeutics for humans. In 2021 and 2022, the Company acquired intellectual property from controlling shareholder, Ainos Inc., a Cayman Islands corporation (“Ainos KY”), and continues to expand its product portfolio into POCTs. Pivoting from the sales of COVID-19 POCT, the Company is commercializing POCTs that detect volatile organic compounds (VOC) emitted by the body, powered by the Company’s AI Nose technology platform. The Company’s lead VOC POCT candidate, Ainos Flora, aims to quickly and easily tests female vaginal health and certain common sexually transmitted infections (STIs). Underwritten Public Offering The Company’s registration statement related to its underwritten public offering (the “Offering”) was declared effective on August 8, 2022, and the Company’s common stock and warrants began trading on the Nasdaq Capital Market (the “Nasdaq”) on August 9, 2022 under the trading symbols “AIMD” and “AIMDW”, respectively. The Company completed its underwritten public offering of an aggregated 780,000 units at a public offering price of $4.25 per unit. Each unit issued in the offering consisted of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $4.25. In connection with the Offering, the Company’s board of directors on April 29, 2022 and its shareholders on May 16, 2022 approved a 1-for-15 reverse stock split (the “Reverse Stock Split”) of the Company’s common stock prior to the effective date of the Offering. The par value and authorized shares of the Company’s common stock were not adjusted as a result of the Reverse Stock Split. All issued and outstanding common stock, restricted stock units (RSUs), outstanding convertible notes, warrants and options to purchase common stock and per share amounts contained in the financial statements have been retroactively adjusted to give effect to the Reverse Stock Split for all periods presented. The Company filed a Certificate of Amendment to its Restated Certificate of Formation with the Secretary of State of Texas on August 8, 2022 that effectuated the Reverse Stock Split.

780000

4.25

1-for-15

2. Summary of Significant Accounting Policies Basis of Presentation The accompanying condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (the “GAAP”) and pursuant to the accounting disclosure rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed financial statements should be read in conjunction with the financial statements and notes included in the Company’s audited financial statements as of and for the year ended December 31, 2022 contained in the Annual Report on Form 10-K filed with the SEC on April 3, 2023. In the opinion of management, the accompanying condensed financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods. The results for the three and six months ended June 30, 2023 are not necessarily indicative of the results to be expected for any subsequent quarter, the year ending December 31, 2023, or any other period. There have been no material changes to the Company’s significant accounting policies as described in the audited financial statements as of December 31, 2022.Use of Estimates The preparation of condensed financial statements in conformity with GAAP requires management to make certain estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and disclosures as of the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates on various factors, including historical experience, and on various other assumptions that are believed to be reasonable under the circumstances, when these carrying values are not readily available from other sources. Significant items subject to estimates and assumptions include useful lives of property and equipment, valuation of stock option and warrants, and impairment testing of intangible assets. Actual results may differ from these estimates. Liquidity As of June 30, 2023, the Company had cash and cash equivalents of $1,360,970. The Company plans to finance its operations and development needs with its existing cash and cash equivalents, additional equity and/or debt financing arrangements, and expected revenue primarily from the sale of VELDONA Pet cytoprotein supplements to support the Company’s clinical trial activities, largely in connection with Ainos Flora and VELDONA therapeutics for humans. There can be no assurance that the Company will be able to obtain additional financing on terms acceptable to the Company, on a timely basis, or at all. If the Company is not able to obtain sufficient funds on acceptable terms when needed, the Company’s business, results of operations, and financial condition could be materially adversely impacted. For the six months ended June 30, 2023, the Company generated a net loss of $4,870,202. The Company expects to continue incurring development expenses for the next twelve months as the Company advances Ainos Flora and VELDONA therapeutics for humans through clinical development until regulatory approval is received and the sales and marketing of the products are authorized. The financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net operating losses in every year since inception and has an accumulated deficit as of June 30, 2023 of $28,985,808 and expects to incur additional losses and negative operating cash flows for at least the next twelve months. The Company’s ability to meet its obligations is dependent upon its ability to generate sufficient cash flows from operations and future financing transactions. Although management expects the Company will continue as a going concern, there is no assurance that management’s plans will be successful since the availability and amount of such funding is not certain. Accordingly, substantial doubt exists about the Company’s ability to continue as a going concern for at least one year from the issuance of these financial statements. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern. Segments Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the chief operating decision maker (the “CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s Chief Executive Officer is the Company’s CODM. The CODM reviews financial information prepared on the basis of accounting policy disclosed in its annual financial statement for purposes of making operating decisions, allocating resources, and evaluating financial performance of the Company. As such, the Company has determined that it operates as one operating segment. Impairment of Intangible Assets The Company reviews its definite-lived intangibles and other long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be fully recoverable. When such events occur, management determines whether there has been impairment by comparing the anticipated undiscounted future net cash flows to the carrying value of the asset or asset group. If impairment exists, the assets are written down to their estimated fair value. No impairment of definite-lived intangible and long-lived assets was recorded for the three and six months ended June 30, 2023 and 2022.Recent Accounting Pronouncements Adopted On January 1, 2023, the Company adopted Accounting Standards Update (the “ASU”) 2016-13 (the “ASU 2016-13”), Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which the Financial Accounting Standards Board (the “FASB”) issued in June 2016. The new standard changes the accounting for credit losses for financial assets and certain other instruments, including trade receivables and contract assets that are not measured at fair value through net income. Under legacy standards, the Company recognizes an impairment of receivables when it was probable that a loss had been incurred. Under the new standard pursuant to ASU 2016-13, the Company is required to recognize estimated credit losses expected to occur over the estimated life or remaining contractual life of an asset (which includes losses that may be incurred in future periods) using a broader range of information including reasonable and supportable forecasts about future economic conditions. The guidance is effective for smaller reporting companies (the “SRC”) as defined by the SEC for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years with early adoption permitted. The Company’s adoption of this new guidance did not have a material impact on the Company’s financial statements and related disclosure. On January 1, 2023, the Company early adopted ASU 2020-06 (the “ASU 2020-06”), Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 as issued by FASB in August 2020 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for SRC’s fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. The Company’s early adoption of this new guidance did not have a material impact on its financial statements and related disclosures. Accounting Standards Issued but Not Yet Adopted No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s financial statements.

The accompanying condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (the “GAAP”) and pursuant to the accounting disclosure rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed financial statements should be read in conjunction with the financial statements and notes included in the Company’s audited financial statements as of and for the year ended December 31, 2022 contained in the Annual Report on Form 10-K filed with the SEC on April 3, 2023. In the opinion of management, the accompanying condensed financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods. The results for the three and six months ended June 30, 2023 are not necessarily indicative of the results to be expected for any subsequent quarter, the year ending December 31, 2023, or any other period. There have been no material changes to the Company’s significant accounting policies as described in the audited financial statements as of December 31, 2022.

The preparation of condensed financial statements in conformity with GAAP requires management to make certain estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and disclosures as of the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates on various factors, including historical experience, and on various other assumptions that are believed to be reasonable under the circumstances, when these carrying values are not readily available from other sources. Significant items subject to estimates and assumptions include useful lives of property and equipment, valuation of stock option and warrants, and impairment testing of intangible assets. Actual results may differ from these estimates.

As of June 30, 2023, the Company had cash and cash equivalents of $1,360,970. The Company plans to finance its operations and development needs with its existing cash and cash equivalents, additional equity and/or debt financing arrangements, and expected revenue primarily from the sale of VELDONA Pet cytoprotein supplements to support the Company’s clinical trial activities, largely in connection with Ainos Flora and VELDONA therapeutics for humans. There can be no assurance that the Company will be able to obtain additional financing on terms acceptable to the Company, on a timely basis, or at all. If the Company is not able to obtain sufficient funds on acceptable terms when needed, the Company’s business, results of operations, and financial condition could be materially adversely impacted. For the six months ended June 30, 2023, the Company generated a net loss of $4,870,202. The Company expects to continue incurring development expenses for the next twelve months as the Company advances Ainos Flora and VELDONA therapeutics for humans through clinical development until regulatory approval is received and the sales and marketing of the products are authorized. The financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net operating losses in every year since inception and has an accumulated deficit as of June 30, 2023 of $28,985,808 and expects to incur additional losses and negative operating cash flows for at least the next twelve months. The Company’s ability to meet its obligations is dependent upon its ability to generate sufficient cash flows from operations and future financing transactions. Although management expects the Company will continue as a going concern, there is no assurance that management’s plans will be successful since the availability and amount of such funding is not certain. Accordingly, substantial doubt exists about the Company’s ability to continue as a going concern for at least one year from the issuance of these financial statements. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.

1360970

-4870202

-28985808

Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the chief operating decision maker (the “CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s Chief Executive Officer is the Company’s CODM. The CODM reviews financial information prepared on the basis of accounting policy disclosed in its annual financial statement for purposes of making operating decisions, allocating resources, and evaluating financial performance of the Company. As such, the Company has determined that it operates as one operating segment.

The Company reviews its definite-lived intangibles and other long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be fully recoverable. When such events occur, management determines whether there has been impairment by comparing the anticipated undiscounted future net cash flows to the carrying value of the asset or asset group. If impairment exists, the assets are written down to their estimated fair value. No impairment of definite-lived intangible and long-lived assets was recorded for the three and six months ended June 30, 2023 and 2022.

On January 1, 2023, the Company adopted Accounting Standards Update (the “ASU”) 2016-13 (the “ASU 2016-13”), Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which the Financial Accounting Standards Board (the “FASB”) issued in June 2016. The new standard changes the accounting for credit losses for financial assets and certain other instruments, including trade receivables and contract assets that are not measured at fair value through net income. Under legacy standards, the Company recognizes an impairment of receivables when it was probable that a loss had been incurred. Under the new standard pursuant to ASU 2016-13, the Company is required to recognize estimated credit losses expected to occur over the estimated life or remaining contractual life of an asset (which includes losses that may be incurred in future periods) using a broader range of information including reasonable and supportable forecasts about future economic conditions. The guidance is effective for smaller reporting companies (the “SRC”) as defined by the SEC for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years with early adoption permitted. The Company’s adoption of this new guidance did not have a material impact on the Company’s financial statements and related disclosure. On January 1, 2023, the Company early adopted ASU 2020-06 (the “ASU 2020-06”), Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 as issued by FASB in August 2020 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for SRC’s fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. The Company’s early adoption of this new guidance did not have a material impact on its financial statements and related disclosures.

No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s financial statements.

3. Cash and Cash Equivalents As of June 30, 2023 and December 31, 2022, cash and cash equivalents consist of cash on hand and cash in bank which is potentially subject to concentration of credit risk. Such balance is maintained at financial institutions that management determines to be of high-credit quality. Cash accounts at each institution are insured by the Federal Deposit Insurance Corporation in the U.S.A or Central Deposit Insurance Corporation in Taiwan up to certain limits. At times, such deposits may be in excess of the insurance limit. The Company has not experienced any losses on its deposits.

4. Inventory Inventory stated at cost, net of reserve, consisted of the following: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">June 30,</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">December 31,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Raw materials</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">354,175</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">393,253</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Work in process</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">67,736</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">111,119</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Finished goods</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">106,203</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">90,850</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">528,114</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">595,222</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> Inventory write-downs to estimated net realizable values were $14,694 and $ 57,474 for the three and six months ended June 30, 2023, respectively, compared to nil for the three and six months ended June 30, 2022. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">June 30,</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">December 31,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Raw materials</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">354,175</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">393,253</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Work in process</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">67,736</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">111,119</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Finished goods</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">106,203</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">90,850</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">528,114</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">595,222</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

354175

393253

67736

111119

106203

90850

528114

595222

14694 57474

5. Convertible Notes Payable and Other Notes Payable As of June 30, 2023 and December 31, 2022, the respective notes payable was as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30,2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31,2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Convertible notes payable, related party – current</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">376,526</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Other notes payable, related party - current</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">684,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">884,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">March 2025 Convertible Notes, related party - noncurrent</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,500,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">March 2025 Convertible Notes - noncurrent</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,000,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,184,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,260,526</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> The Company received funding in the form of convertible promissory note from Dr. Stephen T. Chen, the former Chief Executive Officer or Chen, (the “Chen Note”) in 2016 for the purpose of supporting working capital. The Chen Note is payable on demand and can be converted into common stock of the Company any time at the conversion price of $2.52 or $2.81 per share. The Chen Note bears an interest rate of 0.75% or 0.65%. During the three months ended June 30, 2023, $114,026 of the Chen Note was paid off in cash and the remaining $262,500 of the Chen Note was assigned by Chen to unrelated parties who exercised the conversion right and converted the Chen Note into 93,333 shares of common stock of the Company. The accrued interest expense related to the converted Chen Note was waived by Chen and the assigned parties. The other notes payable were issued to Ainos KY, which is the controlling shareholder of the Company, in exchange for $800,000 in cash to support working capital of the Company in March 2022 (the “KY Note”). The Company paid off $200,000 of the KY Note during the six months ended June 30, 2023. Another notes payable was issued to i2China in exchange for consulting service in 2020 (the “i2China Note”) which remains outstanding for the amount of $84,000 as of June 30, 2023. Both other notes payable bear an interest rate of 1.85% per annum. All of the aforementioned convertible promissory notes and other notes payable are unsecured and due upon maturity. The Company may prepay the notes in whole or in part at any time. The holder of convertible notes has the option to convert some or all of the unpaid principal and accrued interest to common stock of the Company. In July and August 2023, the Company paid off $300,000 of the KY Note and $42,000 of the i2China Note together with the accrued interest and the remaining principal amount is $300,000 and $42,000 for KY Note and i2China Note, respectively. March 2025 Convertible Notes On March 13, 2023, the Company entered into two convertible promissory note purchase agreements pursuant to Regulation S of the Securities Act of 1933 in the total principal amount of $3,000,000 with the following investors (the “March 2025 Convertible Notes” or “Notes”). Convertible Note Issued to ASE Test, Inc. (the “ASE Note”) Pursuant to the aforementioned agreement, ASE Test, Inc., a shareholder of Ainos KY, committed to pay a total aggregate amount of $2,000,000 to the Company in exchange for convertible promissory note(s) in three tranches in the amounts of $1,000,000 (the “First Tranche”), $500,000 (the “Second Tranche”), and $500,000 (the “Third Tranche”) which is conditioned, among other things, on the Company achieving certain business milestones. As of June 30, 2023, the Company received $1,500,000 in cash for the First Tranche and Second Tranche upon achieving pre-defined business milestones. The Third Tranche is pending on the achievement of milestone by the Company. Convertible Note Issued to Li-Kuo Lee (the “Lee Note”) The Company issued a convertible note to an unrelated party, Li-Kuo Lee in exchange of $1,000,000 in cash. As of June 30, 2023, the Company received the full amount of the payment. The March 2025 Convertible Notes will mature in two years from the issuance dates, bearing interest at the rate of 6% compounded interest per annum. At any time after the issuance and before the maturity date, the Notes are convertible into the common stock of the Company at the conversion price of $1.50 per share, subject to anti-dilutive adjustment as set forth in the Notes. Unless previously converted, the Company shall repay the outstanding principal amount plus all accrued and unpaid interest on the maturity date. The Notes shall be an unsecured general obligation of the Company. The total interest expense of convertible notes payable and other notes payable for the three and six months ended June 30, 2023 were $37,991 and $44,924, respectively, compared with the three and six months ended June 30, 2022 of $18,602 and $34,486, respectively. As of June 30, 2023 and December 31, 2022, the unpaid accrued interest expense was $64,795 and $35,282, respectively, among which $37,562 and nil was long-term liabilities, respectively.

684000

884000

1500000 0

1000000

3184000

1260526

price of $2.52 or $2.81 per share

rate of 0.75% or 0.65%.

114026 262500

93333

800000

200000

84000

0.0185

300000 42000

300000

42000

3000000 ASE Test, Inc., a shareholder of Ainos KY, committed to pay a total aggregate amount of $2,000,000 to the Company in exchange for convertible promissory note(s) in three tranches in the amounts of $1,000,000 (the “First Tranche”), $500,000 (the “Second Tranche”), and $500,000 (the “Third Tranche”) which is conditioned, among other things, on the Company achieving certain business milestones.

1000000

0.06

1.50

37991

44924

18602

34486

64795

35282

37562

6. Stockholders’ Equity Common Stock During the three months ended June 30, 2023, the Company issued an additional 281,022 shares of common stock as a result of delivering 126,532 shares to settle vested RSUs, an additional 93,333 shares for the conversion of Chen Note (see Note 5), and 61,157 shares in exchange for a vehicle with a related party (see Note 11). As of June 30, 2023, there were 20,292,624 shares of common stock legally issued and outstanding. Warrants As of June 30, 2023 and December 31, 2022, warrants issued and outstanding in connection with financing are summarized as below: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">June 30,</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">December 31,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"> (In number of shares)</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Public warrant with exercise price of $4.25</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">897,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">897,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Private warrant with exercise price of $4.675</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">39,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">39,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">936,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">936,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> As disclosed in Note 1, the Company issued public warrants together with common stocks in connection with its underwritten public offering effective August 8, 2022. The Company further issued private warrants to Maxim Group LLC, as representative of underwriter pursuance to an underwriting agreement. Each warrant has a contractual term of 5 years, expiring on August 8, 2027, and can be exercised for the purchase of one share of common stock of the Company. The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the instruments’ specific terms and applicable authoritative guidance in ASC 480, Distinguishing Liabilities from Equity (the “ASC480), and ASC 815, Derivatives and Hedging (the “ASC 815”). The assessment considers whether the instruments are free standing financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the instruments meet all of the requirements for equity classification under ASC 815, including whether the instruments are indexed to the Company’s own common shares and whether the instrument holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent period end date while the instruments are outstanding. Management has concluded that the warrants issued in connection with the underwritten public offering qualify for equity accounting treatment and recorded in the additional paid-in capital. In addition, the warrant issued by the Company to i2China in 2020 in exchange for consulting services is accounted for under ASC 718, Compensation - Stock Compensation. Refer to Note 8. As of June 30, 2023, none of the warrants have been exercised nor have expired.

281022

126532

93333

61157

20292624

936000

of 5 years, expiring on August 8, 2027

7. Revenue Revenue is recognized upon shipment of products based upon contractually stated pricing at standard payment terms within 30 days. The revenue generated by product sales is recognized at point in time. For the three and six months ended June 30, 2023 and 2022, the Company generated revenue solely from sales of COVID-19 Antigen Rapid Test Kits in the Taiwan market. There was no revenue recognized from performance obligation satisfied or partially satisfied in prior periods, nor were there any unsatisfied performance obligations as of June 30, 2023 and December 31, 2022.

8. Share-Based Compensation 2023 Stock Incentive Plan The Company effectuated an amendment to its 2021 Stock Incentive Plan, now restated as the Company 2023 Stock Incentive Plan (the “2023 SIP” or “Plan”) which includes, among other things, a change in the number of reserved shares under the Plan. Under the 2023 SIP, subject to a change in capital structure or a change in control, the aggregate number of shares which may be issued or transferred pursuant to awards under the Plan will be equal to up to twenty percent (20%) of shares of outstanding common stock of the Company existing as of December 31st of the previous calendar year (the “Plan Share Reserve”). Upon the effectiveness of the 2023 SIP on June 14, 2023, the aggregate number of shares which may be issued pursuant to awards under the Plan is 4,355,376 shares of common stock, including shares that remained available for grant under the 2021 Stock Incentive Plan. As of June 30, 2023, no shares have been granted under the 2023 SIP. 2021 Stock Incentive Plan On September 28, 2021, the Company’s board of directors, and on May 16, 2022, its shareholders approved the 2021 Stock Incentive Plan (the “2021 SIP”). During the period from January 1, 2023 up to the date that the prior plan was superseded by the 2023 SIP, no shares were granted under the 2021 SIP. 2021 Employee Stock Purchase Plan On September 28, 2021, the Company’s board of directors, and on May 16, 2022, its shareholders approved the 2021 Employee Stock Purchase Plan (the “2021 ESPP”). As of June 30, 2023, no shares were issued under the 2021 ESPP. Restricted Stock Units (“RSUs”) RSUs entitle the recipient to be paid out an equal number of common stock shares upon vesting. The fair value of RSUs is based on market price of the underlying stock on the date of grant. A summary of the Company’s RSUs activity and related information for the three and six months ended June 30, 2022 was Nil and for the three and six months ended June 30, 2023 was as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> Number of Share</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">Weighted-Average Grant Date FairValue Per Share</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Unvested balance at December 31, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">800,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">2.42</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">RSUs granted</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">RSUs vested*</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(29,332</td><td style="vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">11.10</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">RSUs forfeited</td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">(38,000</td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">1.43</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Unvested balance at March 31, 2023</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">732,668</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.12</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">RSUs granted</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">RSUs vested**</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(101,100</td><td style="vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.34</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">RSUs forfeited</td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">(34,850</td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">1.27</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Unvested balance at June 30, 2023</td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;text-align:right;">596,718</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;text-align:right;">2.30</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td></tr></tbody></table> * The common stock underlying the vested RSUs was delivered to grantees during the three months ended June 30, 2023.** 3,900 shares of vested RSUs have not been settled by issuance of common shares to grantees as of June 30, 2023. Stock Options and Warrants During the three and six months ended June 30, 2023 and 2022, no shares were granted, forfeited, expired or exercised. As of June 30, 2023, there were 36,666 shares in the form of stock options and 30,174 shares in the form of warrants outstanding.Share-Based Compensation Expense Shared-based compensation expense for the three and six months ended June 30, 2023 were $137,159 and $357,991, respectively, compared to the three and six months ended June 30, 2022 amount of $43,443 and $86,886, respectively. As of June 30, 2023, the total unrecognized compensation cost related to outstanding RSUs, stock options and warrants was $1,439,499, which the Company expects to recognize over a weighted-average period of 1.85 years.

4355376

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> Number of Share</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">Weighted-Average Grant Date FairValue Per Share</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Unvested balance at December 31, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">800,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">2.42</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">RSUs granted</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">RSUs vested*</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(29,332</td><td style="vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">11.10</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">RSUs forfeited</td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">(38,000</td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">1.43</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Unvested balance at March 31, 2023</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">732,668</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.12</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">RSUs granted</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">RSUs vested**</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(101,100</td><td style="vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.34</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">RSUs forfeited</td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">(34,850</td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">1.27</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Unvested balance at June 30, 2023</td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;text-align:right;">596,718</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;text-align:right;">2.30</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td></tr></tbody></table>

800000

2.42

29332

11.10

38000

1.43

732668

2.12

101100

1.34

34850

1.27

596718

2.30

3900

36666

30174

137159

357991

43443

86886

1439499

P1Y10M6D

9. Income Taxes The Company did not record a federal, state, or foreign income tax provision or benefit for the three or six months ended June 30, 2023 and 2022 due to the expected loss before income taxes to be incurred for the years ended December 31, 2023 and 2022, as well as the Company’s continued maintenance of a full valuation allowance against its net deferred tax assets due to its historical deficit.

10. Net Loss per Common Share The following table sets forth the computation of the basic and diluted net loss per share attributable to common stockholders: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Three Months Ended June 30,</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Six Months Ended June 30,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net loss attributable to common stockholders, basic and diluted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,349,727</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,954,032</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4,870,202</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4,053,927</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted-average number of shares used in computing net loss per share attributable to common stockholders, basic and diluted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,095,705</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,625,133</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,053,886</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,625,133</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net loss per share attributable to common stockholders, basic and diluted</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.12</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.20</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.24</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.42</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table> The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding because they would be anti-dilutive: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Three Months Ended June 30,</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> Six Months Ended June 30,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Option and RSUs to purchase common stock</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">633,384</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">36,666</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">633,384</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">36,666</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Warrants to purchase common stock</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">966,174</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,174</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">966,174</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,174</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Convertible note to purchase common stock</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,666,667</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">9,197,405</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,666,667</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">9,197,405</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total potential shares</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,266,225</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">9,264,245</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,266,225</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">9,264,245</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Three Months Ended June 30,</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Six Months Ended June 30,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net loss attributable to common stockholders, basic and diluted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,349,727</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,954,032</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4,870,202</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4,053,927</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted-average number of shares used in computing net loss per share attributable to common stockholders, basic and diluted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,095,705</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,625,133</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,053,886</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,625,133</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net loss per share attributable to common stockholders, basic and diluted</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.12</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.20</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.24</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.42</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table>

-2349727 -1954032 -4870202 -4053927 20095705 9625133 20053886 9625133 -0.12 -0.20 -0.24 -0.42

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Three Months Ended June 30,</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> Six Months Ended June 30,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Option and RSUs to purchase common stock</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">633,384</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">36,666</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">633,384</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">36,666</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Warrants to purchase common stock</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">966,174</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,174</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">966,174</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,174</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Convertible note to purchase common stock</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,666,667</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">9,197,405</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,666,667</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">9,197,405</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total potential shares</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,266,225</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">9,264,245</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,266,225</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">9,264,245</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

633384

36666

633384

36666

966174 30174 966174 30174 1666667 9197405 1666667 9197405

3266225

9264245

3266225

9264245

11. Related Party Transactions The following is a summary of related party transactions that met our disclosure threshold: Asset Purchase Agreement Ainos KY and the Company entered into an Asset Purchase Agreement dated as of November 18, 2021 (the “Asset Purchase Agreement”), as modified by an Amended and Restated Asset Purchase Agreement dated as of January 29, 2022 (the “Amended Asset Purchase Agreement”). Pursuant to the Asset Purchase Agreement, the Company acquired certain intellectual property assets and certain manufacturing, testing, and office equipment for a total purchase price of $26,000,000 that included $24,886,023 for intangible intellectual property assets and $1,113,977 for equipment. As consideration the Company issued to Ainos KY a convertible promissory note in the principal amount of $26,000,000 upon closing on January 30, 2022 (the “APA Convertible Note”). Ainos KY converted all of the APA Convertible Note on or about August 8, 2022 upon the Company’s up-listing to the Nasdaq Capital Markets.Working Capital Advances Refer to Chen Note, KY Note and ASE Note in Note 5 which proceeds were used for working capital advances. The total interest expense incurred in related to the notes for the three and six months ended June 30, 2023 were $23,031 and $26,841, respectively, compared to $18,602 and $34,486, respectively, for the three and six months ended June 30, 2022. As of June 30, 2023 and December 31, 2022, unpaid accrued interest expenses were $46,712 and $35,282, respectively. Purchase and Sales Ainos COVID-19 Test Kits Sales and Marketing Agreement with Ainos KY On June 14, 2021, the Company entered into an exclusive agreement with Ainos KY to serve as the master sales and marketing agent for the Ainos COVID-19 Antigen Rapid Test Kit and COVID-19 Nucleic Acid Test Kit which were developed and will be manufactured by Taiwan Carbon Nano Technology Corporation (the “TCNT”), a controlling shareholder of Ainos KY (the “Sales and Marketing Agreement”). On June 7, 2021, the Taiwan Food and Drug Administration (the “TFDA”) approved emergency use authorization (the “EUA”) to TCNT for the Ainos COVID-19 Antigen Rapid Test Kit that will be sold and marketed under the “Ainos” brand in Taiwan. On June 21, 2022, the Company began marketing the Ainos SARS-CoV-2 Antigen Rapid Self-Test (together with Ainos COVID-19 Antigen Rapid Test Kit, the “COVID-19 Antigen Rapid Test Kits”) under a separate EUA issued by the TFDA to TCNT on June 13, 2022. The Company incurred costs associated with manufacturing COVID-19 Antigen Rapid Test Kits by TCNT pursuant to the Sales and Marketing Agreement, totaling nil and $46,635 for the three and six months ended June 30, 2023, respectively, compared with the amount for the three and six months ended June 30, 2022 of $483,992 and $870,404, respectively. As of June 30, 2023 and December 31, 2022, the accounts payable to TCNT were nil and $24,365, respectively; the prepayment to TCNT were $90,519 and nil, respectively. COVID-19 Antigen Rapid Test Kits Sales The Company sold COVID-19 Antigen Rapid Test Kits to affiliates of ASE Test Inc., totaling $12,541 and $12,541 for the three and six months ended June 30, 2023, respectively, compared with the amount for the three and six months ended June 30, 2022 of $401,259 and $482,359, respectively. As of June 30, 2023, and December 31, 2022, the accounts receivable to aforementioned related parties were nil and $177,595, respectively. Product Co-development Agreement Pursuant to a five-year Product Co-development Agreement effective on August 1, 2021 (the “Product Co-Development Agreement”) with TCNT, the development expenses incurred were $74,733 and $152,196 for the three and six months ended June 30, 2023, respectively, compared to $206,748 and $374,170 for the three and six months ended June 30, 2022, respectively. As of June 30, 2023 and December 31, 2022, the accounts payable were $25,089 and $70,113, respectively. Under the agreement, the Company made deposits of $31,071 and $31,490 to TCNT as of June 30, 2023 and December 31, 2022, respectively. Miscellaneous On April 26, 2023, the Company issued a total of 61,157 shares of common stock to Ting-Chuan Lee, a director of the Company, pursuant to a purchase and sale agreement relating to the Company’s acquisition of a vehicle. The purchase price was determined by the market price of the vehicle in the amount of $48,559. The Company engaged Ms. Chien-Hsuan Huang as a medical device development consultant in September 2022. Ms. Huang is the spouse of one of the board of directors of the Company. The R&D expense was $19,618 and $39,344 for the three and six months ended June 30, 2023, respectively.

26000000 24886023

1113977

26000000

23031 26841 18602 34486

46712

35282

46635 483992 870404 24365 90519 12541 12541 401259 482359

177595

74733

152196

206748

374170

25089 70113

31071

31490

61157

48559

19618

39344

12. Commitments and Contingencies The Company operates in an industry characterized by extensive patent litigation. Competitors may claim that the Company’s products infringe upon their intellectual property. Resolution of patent litigation or other intellectual property claims is typically time consuming and costly and can result in significant damage awards and injunctions that could prevent the manufacture and sale of the affected products or require the Company to make significant royalty payments in order to continue selling the affected products. As of June 30, 2023, there were no such commitments or contingencies.

13. Subsequent Events On August 9, 2023, the Company entered into a Co-Development Agreement (the “Agreement”) with Nisshinbo Micro Devices Inc., a Japan corporation (“NISD”), and Taiwan Inabata Sangyo Co., Ltd., a Taiwan corporation (“Inabata”). Pursuant to the Agreement, NISD will outsource development of the odor platform and delivery of gas sensor products to the Company. Inabata is responsible for coordinating the co-development effort between NISD and the Company. The Company will provide the deliverables in phases and performance obligations will be satisfied upon NISD’s acceptance. The total contract price is variable based on the quantity specified by NISD for future purchase orders. The Agreement is effective August 9, 2023 and expires on August 31, 2026.

EXCEL 51 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
V_Y55^M>/X\E]9;OZK[!OV>FP/L;=N\N(03":'8/( :C).WZ3'L#T: MM\[?G=.WBP;PEI.1[_"V)#9)@\F""\-EVYOS/&?RR2%LY0V=V%?9'7T[/F<% M70ASUX$9V;2_L9PORK0;=0,+T8[:M+_"]**D>\6RN;C,V9+EX[:K9Y.F&=B& MS=I>0-A'KIO+CV (<_7 M ;:GSU4(-E.\$K&9XFL-B'_=@)&F_MW&\@ #VP6L=B"_/P_4E)\3Q["KF#?L M"<:1-,40J$5_C28)LCH)?/S[@STE<9RF?@0POX,XQA!X&G$$
,"2.FW-P M[SP*U^=4N/E]9_0;4$L#!!0 ( ."!"U>7BKL
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end XML 52 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 53 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 54 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 110 203 1 false 22 0 false 4 false false R1.htm 000001 - Document - Cover Sheet http://aimd.com/role/Cover Cover Cover 1 false false R2.htm 000002 - Statement - Condensed Balance Sheets Sheet http://aimd.com/role/CondensedBalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 000003 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://aimd.com/role/CondensedBalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 000004 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://aimd.com/role/CondensedStatementsOfOperationsUnaudited Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 000005 - Statement - Condensed Statements of Comprehensive Loss (Unaudited) Sheet http://aimd.com/role/CondensedStatementsOfComprehensiveLossUnaudited Condensed Statements of Comprehensive Loss (Unaudited) Statements 5 false false R6.htm 000006 - Statement - Condensed Statements of Stockholders Equity (Unaudited) Sheet http://aimd.com/role/CondensedStatementsOfStockholdersEquityUnaudited Condensed Statements of Stockholders Equity (Unaudited) Statements 6 false false R7.htm 000007 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited Condensed Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 000008 - Disclosure - Description of Business Sheet http://aimd.com/role/DescriptionOfBusiness Description of Business Notes 8 false false R9.htm 000009 - Disclosure - Summary of Significant Accounting Policies Sheet http://aimd.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 000010 - Disclosure - Cash and Cash Equivalents Sheet http://aimd.com/role/CashAndCashEquivalents Cash and Cash Equivalents Notes 10 false false R11.htm 000011 - Disclosure - Inventory Sheet http://aimd.com/role/Inventory Inventory Notes 11 false false R12.htm 000012 - Disclosure - Convertible Notes Payable and Other Notes Payable Notes http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayable Convertible Notes Payable and Other Notes Payable Notes 12 false false R13.htm 000013 - Disclosure - Stockholders Equity Sheet http://aimd.com/role/StockholdersEquity Stockholders Equity Notes 13 false false R14.htm 000014 - Disclosure - Revenue Sheet http://aimd.com/role/Revenue Revenue Notes 14 false false R15.htm 000015 - Disclosure - ShareBased Compensation Sheet http://aimd.com/role/SharebasedCompensation ShareBased Compensation Notes 15 false false R16.htm 000016 - Disclosure - Income Taxes Sheet http://aimd.com/role/IncomeTaxes Income Taxes Notes 16 false false R17.htm 000017 - Disclosure - Net Loss per Common Share Sheet http://aimd.com/role/NetLossPerCommonShare Net Loss per Common Share Notes 17 false false R18.htm 000018 - Disclosure - Related Party Transactions Sheet http://aimd.com/role/RelatedPartyTransactions Related Party Transactions Notes 18 false false R19.htm 000019 - Disclosure - Commitments and Contingencies Sheet http://aimd.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 19 false false R20.htm 000020 - Disclosure - Subsequent Events Sheet http://aimd.com/role/SubsequentEvents Subsequent Events Notes 20 false false R21.htm 000021 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) Sheet http://aimd.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies Organization and Summary of Significant Accounting Policies (Policies) Policies http://aimd.com/role/SummaryOfSignificantAccountingPolicies 21 false false R22.htm 000022 - Disclosure - Inventory (Tables) Sheet http://aimd.com/role/InventoryTables Inventory (Tables) Tables http://aimd.com/role/Inventory 22 false false R23.htm 000023 - Disclosure - Convertible Notes Payable and Other Notes Payable (Tables) Notes http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableTables Convertible Notes Payable and Other Notes Payable (Tables) Tables http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayable 23 false false R24.htm 000024 - Disclosure - Stockholders Equity (Tables) Sheet http://aimd.com/role/StockholdersEquityTables Stockholders Equity (Tables) Tables http://aimd.com/role/StockholdersEquity 24 false false R25.htm 000025 - Disclosure - ShareBased Compensation (Tables) Sheet http://aimd.com/role/SharebasedCompensationTables ShareBased Compensation (Tables) Tables http://aimd.com/role/SharebasedCompensation 25 false false R26.htm 000026 - Disclosure - Net Loss per Common Share (Tables) Sheet http://aimd.com/role/NetLossPerCommonShareTables Net Loss per Common Share (Tables) Tables http://aimd.com/role/NetLossPerCommonShare 26 false false R27.htm 000027 - Disclosure - Description of Business (Details Narrative) Sheet http://aimd.com/role/DescriptionOfBusinessDetailsNarrative Description of Business (Details Narrative) Details http://aimd.com/role/DescriptionOfBusiness 27 false false R28.htm 000028 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://aimd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details 28 false false R29.htm 000029 - Disclosure - Inventory (Details) Sheet http://aimd.com/role/InventoryDetails Inventory (Details) Details http://aimd.com/role/InventoryTables 29 false false R30.htm 000030 - Disclosure - Inventory (Details Narrative) Sheet http://aimd.com/role/InventoryDetailsNarrative Inventory (Details Narrative) Details http://aimd.com/role/InventoryTables 30 false false R31.htm 000031 - Disclosure - Convertible Notes Payable and Other Notes Payable (Details) Notes http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetails Convertible Notes Payable and Other Notes Payable (Details) Details http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableTables 31 false false R32.htm 000032 - Disclosure - Convertible Notes Payable and Other Notes Payable (Details Narrative) Notes http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetailsNarrative Convertible Notes Payable and Other Notes Payable (Details Narrative) Details http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableTables 32 false false R33.htm 000033 - Disclosure - Stockholders Equity (Details) Sheet http://aimd.com/role/StockholdersEquityDetails Stockholders Equity (Details) Details http://aimd.com/role/StockholdersEquityTables 33 false false R34.htm 000034 - Disclosure - Stockholders Equity (Details Narrative) Sheet http://aimd.com/role/StockholdersEquityDetailsNarrative Stockholders Equity (Details Narrative) Details http://aimd.com/role/StockholdersEquityTables 34 false false R35.htm 000035 - Disclosure - ShareBased Compensation (Details) Sheet http://aimd.com/role/SharebasedCompensationDetails ShareBased Compensation (Details) Details http://aimd.com/role/SharebasedCompensationTables 35 false false R36.htm 000036 - Disclosure - ShareBased Compensation (Details Narrative) Sheet http://aimd.com/role/SharebasedCompensationDetailsNarrative ShareBased Compensation (Details Narrative) Details http://aimd.com/role/SharebasedCompensationTables 36 false false R37.htm 000037 - Disclosure - Net Loss per Common Share (Details) Sheet http://aimd.com/role/NetLossPerCommonShareDetails Net Loss per Common Share (Details) Details http://aimd.com/role/NetLossPerCommonShareTables 37 false false R38.htm 000038 - Disclosure - Net Loss per Common Share (Details 1) Sheet http://aimd.com/role/NetLossPerCommonShareDetails1 Net Loss per Common Share (Details 1) Details http://aimd.com/role/NetLossPerCommonShareTables 38 false false R39.htm 000039 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://aimd.com/role/RelatedPartyTransactions 39 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 21 fact(s) appearing in ix:hidden were eligible for transformation: aimd:AccountsPayableRelatedParty, aimd:AccountsReceivableRelatedPartyCurrent, aimd:ConvertibleNotesPayableNoncurrentRelatedParty, aimd:EstimatedNetRealizableValues, aimd:PrepaymentToRelatedParty, aimd:totaling, us-gaap:AccountsReceivableNet, us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:PreferredStockParOrStatedValuePerShare, us-gaap:PreferredStockSharesIssued - aimd_10q.htm 1 aimd_10q.htm aimd-20230630.xsd aimd-20230630_cal.xml aimd-20230630_def.xml aimd-20230630_lab.xml aimd-20230630_pre.xml aimd_ex311.htm aimd_ex312.htm aimd_ex321.htm aimd_ex322.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 57 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "aimd_10q.htm": { "axisCustom": 0, "axisStandard": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 382, "http://xbrl.sec.gov/dei/2022": 33 }, "contextCount": 110, "dts": { "calculationLink": { "local": [ "aimd-20230630_cal.xml" ] }, "definitionLink": { "local": [ "aimd-20230630_def.xml" ] }, "inline": { "local": [ "aimd_10q.htm" ] }, "labelLink": { "local": [ "aimd-20230630_lab.xml" ] }, "presentationLink": { "local": [ "aimd-20230630_pre.xml" ] }, "schema": { "local": [ "aimd-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 277, "entityCount": 1, "hidden": { "http://aimd.com/20230630": 8, "http://fasb.org/us-gaap/2022": 13, "http://xbrl.sec.gov/dei/2022": 5, "total": 26 }, "keyCustom": 50, "keyStandard": 153, "memberCustom": 16, "memberStandard": 6, "nsprefix": "aimd", "nsuri": "http://aimd.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://aimd.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000010 - Disclosure - Cash and Cash Equivalents", "menuCat": "Notes", "order": "10", "role": "http://aimd.com/role/CashAndCashEquivalents", "shortName": "Cash and Cash Equivalents", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "aimd:InventoryTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000011 - Disclosure - Inventory", "menuCat": "Notes", "order": "11", "role": "http://aimd.com/role/Inventory", "shortName": "Inventory", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "aimd:InventoryTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000012 - Disclosure - Convertible Notes Payable and Other Notes Payable", "menuCat": "Notes", "order": "12", "role": "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayable", "shortName": "Convertible Notes Payable and Other Notes Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000013 - Disclosure - Stockholders Equity", "menuCat": "Notes", "order": "13", "role": "http://aimd.com/role/StockholdersEquity", "shortName": "Stockholders Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredRevenueDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000014 - Disclosure - Revenue", "menuCat": "Notes", "order": "14", "role": "http://aimd.com/role/Revenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredRevenueDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000015 - Disclosure - ShareBased Compensation", "menuCat": "Notes", "order": "15", "role": "http://aimd.com/role/SharebasedCompensation", "shortName": "ShareBased Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000016 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "16", "role": "http://aimd.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "aimd:NetLossPerCommonShareDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000017 - Disclosure - Net Loss per Common Share", "menuCat": "Notes", "order": "17", "role": "http://aimd.com/role/NetLossPerCommonShare", "shortName": "Net Loss per Common Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "aimd:NetLossPerCommonShareDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000018 - Disclosure - Related Party Transactions", "menuCat": "Notes", "order": "18", "role": "http://aimd.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000019 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "19", "role": "http://aimd.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000002 - Statement - Condensed Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://aimd.com/role/CondensedBalanceSheets", "shortName": "Condensed Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000020 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "20", "role": "http://aimd.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000021 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "21", "role": "http://aimd.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Organization and Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "aimd:InventoryTextblock", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "aimd:InventoriesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000022 - Disclosure - Inventory (Tables)", "menuCat": "Tables", "order": "22", "role": "http://aimd.com/role/InventoryTables", "shortName": "Inventory (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "aimd:InventoryTextblock", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "aimd:InventoriesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "aimd:ConvertibleNotesPayableAndOtherNotesPayableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000023 - Disclosure - Convertible Notes Payable and Other Notes Payable (Tables)", "menuCat": "Tables", "order": "23", "role": "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableTables", "shortName": "Convertible Notes Payable and Other Notes Payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "aimd:ConvertibleNotesPayableAndOtherNotesPayableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "aimd:WarrantsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000024 - Disclosure - Stockholders Equity (Tables)", "menuCat": "Tables", "order": "24", "role": "http://aimd.com/role/StockholdersEquityTables", "shortName": "Stockholders Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "aimd:WarrantsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "aimd:ScheduleOfRestrictedStockUnitsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000025 - Disclosure - ShareBased Compensation (Tables)", "menuCat": "Tables", "order": "25", "role": "http://aimd.com/role/SharebasedCompensationTables", "shortName": "ShareBased Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "aimd:ScheduleOfRestrictedStockUnitsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "aimd:NetLossPerCommonShareDisclosureTextBlock", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000026 - Disclosure - Net Loss per Common Share (Tables)", "menuCat": "Tables", "order": "26", "role": "http://aimd.com/role/NetLossPerCommonShareTables", "shortName": "Net Loss per Common Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "aimd:NetLossPerCommonShareDisclosureTextBlock", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000027 - Disclosure - Description of Business (Details Narrative)", "menuCat": "Details", "order": "27", "role": "http://aimd.com/role/DescriptionOfBusinessDetailsNarrative", "shortName": "Description of Business (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "aimd:LiquidityPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000028 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "menuCat": "Details", "order": "28", "role": "http://aimd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "aimd:InventoriesTableTextBlock", "aimd:InventoryTextblock", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000029 - Disclosure - Inventory (Details)", "menuCat": "Details", "order": "29", "role": "http://aimd.com/role/InventoryDetails", "shortName": "Inventory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "aimd:InventoriesTableTextBlock", "aimd:InventoryTextblock", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "000003 - Statement - Condensed Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://aimd.com/role/CondensedBalanceSheetsParenthetical", "shortName": "Condensed Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "p", "aimd:InventoryTextblock", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "aimd:EstimatedNetRealizableValues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000030 - Disclosure - Inventory (Details Narrative)", "menuCat": "Details", "order": "30", "role": "http://aimd.com/role/InventoryDetailsNarrative", "shortName": "Inventory (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "aimd:InventoryTextblock", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "aimd:EstimatedNetRealizableValues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "aimd:ConvertibleNotesPayableAndOtherNotesPayableTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "aimd:ConvertibleNotesPayableRelatedPartyCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000031 - Disclosure - Convertible Notes Payable and Other Notes Payable (Details)", "menuCat": "Details", "order": "31", "role": "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetails", "shortName": "Convertible Notes Payable and Other Notes Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "aimd:ConvertibleNotesPayableAndOtherNotesPayableTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "aimd:ConvertibleNotesPayableRelatedPartyCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "aimd:ConvertibleNotesPayableAndOtherNotesPayableTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ConvertibleNotesPayable", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000032 - Disclosure - Convertible Notes Payable and Other Notes Payable (Details Narrative)", "menuCat": "Details", "order": "32", "role": "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetailsNarrative", "shortName": "Convertible Notes Payable and Other Notes Payable (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30_aimd_ChenMember", "decimals": null, "lang": "en-US", "name": "us-gaap:ConversionOfStockDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "aimd:WarrantsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "AsOf2023-06-30_aimd_WarrantsMember", "decimals": "0", "first": true, "lang": null, "name": "aimd:PublicWarrantWithExercisePrice", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000033 - Disclosure - Stockholders Equity (Details)", "menuCat": "Details", "order": "33", "role": "http://aimd.com/role/StockholdersEquityDetails", "shortName": "Stockholders Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "aimd:WarrantsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "AsOf2023-06-30_aimd_WarrantsMember", "decimals": "0", "first": true, "lang": null, "name": "aimd:PublicWarrantWithExercisePrice", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-04-01to2023-04-26", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ConversionOfStockSharesIssued1", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000034 - Disclosure - Stockholders Equity (Details Narrative)", "menuCat": "Details", "order": "34", "role": "http://aimd.com/role/StockholdersEquityDetailsNarrative", "shortName": "Stockholders Equity (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "AsOf2023-06-30_aimd_CommonSharesMember", "decimals": "0", "lang": null, "name": "us-gaap:CommonStockOtherSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "aimd:ScheduleOfRestrictedStockUnitsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "AsOf2023-03-31_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000035 - Disclosure - ShareBased Compensation (Details)", "menuCat": "Details", "order": "35", "role": "http://aimd.com/role/SharebasedCompensationDetails", "shortName": "ShareBased Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "aimd:ScheduleOfRestrictedStockUnitsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "0", "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000036 - Disclosure - ShareBased Compensation (Details Narrative)", "menuCat": "Details", "order": "36", "role": "http://aimd.com/role/SharebasedCompensationDetailsNarrative", "shortName": "ShareBased Compensation (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "aimd:NetLossPerCommonShareDisclosureTextBlock", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "aimd:EarningsLossAvailableToCommonShareholdersBasicAndDiluted", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000037 - Disclosure - Net Loss per Common Share (Details)", "menuCat": "Details", "order": "37", "role": "http://aimd.com/role/NetLossPerCommonShareDetails", "shortName": "Net Loss per Common Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "aimd:NetLossPerCommonShareDisclosureTextBlock", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "aimd:EarningsLossAvailableToCommonShareholdersBasicAndDiluted", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "aimd:NetLossPerCommonShareDisclosureTextBlock", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesRestrictedStock", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000038 - Disclosure - Net Loss per Common Share (Details 1)", "menuCat": "Details", "order": "38", "role": "http://aimd.com/role/NetLossPerCommonShareDetails1", "shortName": "Net Loss per Common Share (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "aimd:NetLossPerCommonShareDisclosureTextBlock", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "0", "lang": null, "name": "aimd:WeightedAverageSharesOutstandingConvertibleNotePurchaseCommonStock", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "aimd:RepurchaseAgreementsInterestExpenseAmount1", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000039 - Disclosure - Related Party Transactions (Details Narrative)", "menuCat": "Details", "order": "39", "role": "http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "Related Party Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "0", "lang": null, "name": "aimd:InterestExpenseIncurredRelatedParty", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000004 - Statement - Condensed Statements of Operations (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://aimd.com/role/CondensedStatementsOfOperationsUnaudited", "shortName": "Condensed Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000005 - Statement - Condensed Statements of Comprehensive Loss (Unaudited)", "menuCat": "Statements", "order": "5", "role": "http://aimd.com/role/CondensedStatementsOfComprehensiveLossUnaudited", "shortName": "Condensed Statements of Comprehensive Loss (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "0", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "AsOf2021-12-31_aimd_CommonStcksMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000006 - Statement - Condensed Statements of Stockholders Equity (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://aimd.com/role/CondensedStatementsOfStockholdersEquityUnaudited", "shortName": "Condensed Statements of Stockholders Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "AsOf2021-12-31_aimd_CommonStcksMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000007 - Statement - Condensed Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "7", "role": "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited", "shortName": "Condensed Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000008 - Disclosure - Description of Business", "menuCat": "Notes", "order": "8", "role": "http://aimd.com/role/DescriptionOfBusiness", "shortName": "Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000009 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "9", "role": "http://aimd.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aimd_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 22, "tag": { "aimd_AccountsPayableRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accounts payable to related party" } } }, "localname": "AccountsPayableRelatedParty", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "aimd_AccountsReceivableRelatedPartyCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Accounts receivable" } } }, "localname": "AccountsReceivableRelatedPartyCurrent", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "aimd_AggregatePublicOffering": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Aggregate public offering" } } }, "localname": "AggregatePublicOffering", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/DescriptionOfBusinessDetailsNarrative" ], "xbrltype": "sharesItemType" }, "aimd_AinosCOVID19TestKitsSalesandMarketinAgreementwithainosKYMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ainos COVID-19 Test Kits Sales and Marketing Agreement with Ainos KY" } } }, "localname": "AinosCOVID19TestKitsSalesandMarketinAgreementwithainosKYMember", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "aimd_AinosKyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ainos KY [Member]" } } }, "localname": "AinosKyMember", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "aimd_COVID19AntigenRapidTestKitsSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COVID-19 Antigen Rapid Test Kits Sales" } } }, "localname": "COVID19AntigenRapidTestKitsSalesMember", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "aimd_ChenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Chen [Member]" } } }, "localname": "ChenMember", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "aimd_Chien-HsuanHuangMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Mr. Chien-Hsuan Huang [Member]" } } }, "localname": "Chien-HsuanHuangMember", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "aimd_CommonSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Shares [Member]" } } }, "localname": "CommonSharesMember", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "aimd_CommonStcksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock" } } }, "localname": "CommonStcksMember", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/CondensedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "aimd_CommonStockAndShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock And Share [Member]" } } }, "localname": "CommonStockAndShareMember", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/Cover" ], "xbrltype": "domainItemType" }, "aimd_ConversionOfConvertibleNotesPayableToCommonStockAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Conversion of convertible notes payable to common stock, amount" } } }, "localname": "ConversionOfConvertibleNotesPayableToCommonStockAmount", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/CondensedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "aimd_ConversionOfConvertibleNotesPayableToCommonStockAndAccruedInterestWaivedByConvertibleNoteHolders": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Conversion of convertible notes payable to common stock and accrued interest waived by convertible note holders" } } }, "localname": "ConversionOfConvertibleNotesPayableToCommonStockAndAccruedInterestWaivedByConvertibleNoteHolders", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "aimd_ConversionOfConvertibleNotesPayableToCommonStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Conversion of convertible notes payable to common stock, shares" } } }, "localname": "ConversionOfConvertibleNotesPayableToCommonStockShares", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/CondensedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "aimd_ConversionOfStockInExchangeForVehicle": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Conversion of stock in exchange for vehicle" } } }, "localname": "ConversionOfStockInExchangeForVehicle", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "aimd_ConvertibleNotesPayableAndOtherNotesPayableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable and Other Notes Payable" } } }, "localname": "ConvertibleNotesPayableAndOtherNotesPayableAbstract", "nsuri": "http://aimd.com/20230630", "xbrltype": "stringItemType" }, "aimd_ConvertibleNotesPayableAndOtherNotesPayableTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Convertible Notes Payable and Other Notes Payable]", "verboseLabel": "Convertible Notes Payable and Other Notes Payable" } } }, "localname": "ConvertibleNotesPayableAndOtherNotesPayableTableTextBlock", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableTables" ], "xbrltype": "textBlockItemType" }, "aimd_ConvertibleNotesPayableNoncurrent": { "auth_ref": [], "calculation": { "http://aimd.com/role/CondensedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Convertible notes payable (including amounts of related party of $1,500,000 and nil as of June 30, 2023 and December 31, 2022, respectively)" } } }, "localname": "ConvertibleNotesPayableNoncurrent", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "aimd_ConvertibleNotesPayableNoncurrentRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Convertible notes payable" } } }, "localname": "ConvertibleNotesPayableNoncurrentRelatedParty", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "aimd_ConvertibleNotesPayableRelatedPartyCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Convertible notes payable, related party - current" } } }, "localname": "ConvertibleNotesPayableRelatedPartyCurrent", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "aimd_ConvertibleNotesRelatedPartyNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Convertible Notes, related party - noncurrent" } } }, "localname": "ConvertibleNotesRelatedPartyNoncurrent", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "aimd_DescriptionOfBusinessAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Description of Business" } } }, "localname": "DescriptionOfBusinessAbstract", "nsuri": "http://aimd.com/20230630", "xbrltype": "stringItemType" }, "aimd_DescriptionOfConvertibleNoteSaleToAseTestInc": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Description of Convertible Note Sale to ASE Test, Inc" } } }, "localname": "DescriptionOfConvertibleNoteSaleToAseTestInc", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "aimd_EarningsLossAvailableToCommonShareholdersBasicAndDiluted": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Net loss attributable to common stockholders, basic and diluted" } } }, "localname": "EarningsLossAvailableToCommonShareholdersBasicAndDiluted", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "aimd_EstimatedNetRealizableValues": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Estimated net realizable values" } } }, "localname": "EstimatedNetRealizableValues", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/InventoryDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "aimd_ExercisePriceOfShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise price of share" } } }, "localname": "ExercisePriceOfShare", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/DescriptionOfBusinessDetailsNarrative" ], "xbrltype": "perShareItemType" }, "aimd_ITwoChinaNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "i2China [Member]" } } }, "localname": "ITwoChinaNoteMember", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "aimd_IncomeTaxesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes" } } }, "localname": "IncomeTaxesAbstract", "nsuri": "http://aimd.com/20230630", "xbrltype": "stringItemType" }, "aimd_IntangibleAssetsNonCurrent": { "auth_ref": [], "calculation": { "http://aimd.com/role/CondensedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNonCurrent", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "aimd_InterestExpenseIncurredRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Interest expense incurred" } } }, "localname": "InterestExpenseIncurredRelatedParty", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "aimd_InventoriesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventories" } } }, "localname": "InventoriesTableTextBlock", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/InventoryTables" ], "xbrltype": "textBlockItemType" }, "aimd_InventoryAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory" } } }, "localname": "InventoryAbstract", "nsuri": "http://aimd.com/20230630", "xbrltype": "stringItemType" }, "aimd_InventoryTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Inventory]", "verboseLabel": "Inventory" } } }, "localname": "InventoryTextblock", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/Inventory" ], "xbrltype": "textBlockItemType" }, "aimd_IssuanceOfStockInExchangeOfVehicleAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Issuance of stock in exchange of vehicle, amount" } } }, "localname": "IssuanceOfStockInExchangeOfVehicleAmount", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/CondensedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "aimd_IssuanceOfStockInExchangeOfVehicleShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of stock in exchange of vehicle, shares" } } }, "localname": "IssuanceOfStockInExchangeOfVehicleShares", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/CondensedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "aimd_IssuanceOfStockToSettleVestedRsusAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Issuance of stock to settle vested RSUs, amount" } } }, "localname": "IssuanceOfStockToSettleVestedRsusAmount", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/CondensedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "aimd_IssuanceOfStockToSettleVestedRsusShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of stock to settle vested RSUs, shares" } } }, "localname": "IssuanceOfStockToSettleVestedRsusShares", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/CondensedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "aimd_LiKuoLeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Li-Kuo Lee [Member]" } } }, "localname": "LiKuoLeeMember", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "aimd_LiquidityPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liquidity" } } }, "localname": "LiquidityPolicyTextBlock", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "aimd_March2025ConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "March 2025 Convertible Notes [Member]" } } }, "localname": "March2025ConvertibleNotesMember", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetails", "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "aimd_NetEarningsPerShareBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net loss per common share - basic and diluted" } } }, "localname": "NetEarningsPerShareBasicAndDiluted", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "aimd_NetLossPerCommonShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Loss per Common Share" } } }, "localname": "NetLossPerCommonShareAbstract", "nsuri": "http://aimd.com/20230630", "xbrltype": "stringItemType" }, "aimd_NetLossPerCommonShareDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Net Loss per Common Share]", "verboseLabel": "Net Loss per Common Share" } } }, "localname": "NetLossPerCommonShareDisclosureTextBlock", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/NetLossPerCommonShare" ], "xbrltype": "textBlockItemType" }, "aimd_NetLossPerShareAttributableToCommonStockholdersBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net loss per share attributable to common stockholders, basic and diluted" } } }, "localname": "NetLossPerShareAttributableToCommonStockholdersBasicAndDiluted", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "aimd_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Standards Issued but Not Yet Adopted" } } }, "localname": "NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "aimd_NotePaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Note paid" } } }, "localname": "NotePaid", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "aimd_NotesPayablesonConversion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Convertible note payable" } } }, "localname": "NotesPayablesonConversion", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "aimd_OtherNotesPayableRelatedPartycurrent": { "auth_ref": [], "calculation": { "http://aimd.com/role/CondensedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Other notes payable, related party" } } }, "localname": "OtherNotesPayableRelatedPartycurrent", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "aimd_PreferredStock001ParValue10000000SharesAuthorizedNoneIssuedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred stock, $0.01 par value; 10,000,000 shares authorized; none issued" } } }, "localname": "PreferredStock001ParValue10000000SharesAuthorizedNoneIssuedAbstract", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "aimd_PrepaymentToRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Prepayment to related party" } } }, "localname": "PrepaymentToRelatedParty", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "aimd_PrivateWarrantWithExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Private warrant with exercise price of $4.675" } } }, "localname": "PrivateWarrantWithExercisePrice", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "aimd_ProductCoDevelopmentAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Product Co-development Agreement [Member]" } } }, "localname": "ProductCoDevelopmentAgreementMember", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "aimd_PropertyAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Property assets" } } }, "localname": "PropertyAssets", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "aimd_PublicWarrantWithExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Public warrant with exercise price of $4.25" } } }, "localname": "PublicWarrantWithExercisePrice", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "aimd_RepurchaseAgreementsInterestExpenseAmount1": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Assets purchase agrement" } } }, "localname": "RepurchaseAgreementsInterestExpenseAmount1", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "aimd_RevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue" } } }, "localname": "RevenueAbstract", "nsuri": "http://aimd.com/20230630", "xbrltype": "stringItemType" }, "aimd_ScheduleOfRestrictedStockUnitsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Restricted Stock Units" } } }, "localname": "ScheduleOfRestrictedStockUnitsTableTextBlock", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/SharebasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "aimd_SegmentsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segments" } } }, "localname": "SegmentsPolicyTextBlock", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "aimd_StockOptionAndWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock option and Warrants [Member]" } } }, "localname": "StockOptionAndWarrantsMember", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/SharebasedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "aimd_TotalPrincipalAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Total principal amount" } } }, "localname": "TotalPrincipalAmount", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "aimd_TranslationAdjustment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Translation adjustment]", "verboseLabel": "Translation adjustment" } } }, "localname": "TranslationAdjustment", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/CondensedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "aimd_TranslationAdjustmentLiability": { "auth_ref": [], "calculation": { "http://aimd.com/role/CondensedBalanceSheets": { "order": 19.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Translation adjustment" } } }, "localname": "TranslationAdjustmentLiability", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "aimd_TwoThousandTwentyThreeStockIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2023 Stock Incentive Plan" } } }, "localname": "TwoThousandTwentyThreeStockIncentivePlanMember", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/SharebasedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "aimd_UnrelatedParties": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Unrelated parties" } } }, "localname": "UnrelatedParties", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "aimd_VestedRsus": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Vested RSUs" } } }, "localname": "VestedRsus", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "aimd_WarrantsExpiringTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants expiring term" } } }, "localname": "WarrantsExpiringTerm", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "aimd_WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants [Member]" } } }, "localname": "WarrantsMember", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "aimd_WarrantsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants" } } }, "localname": "WarrantsTableTextBlock", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "aimd_WarrantsToPurchaseCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants To Purchase Common Stock [Member]" } } }, "localname": "WarrantsToPurchaseCommonStockMember", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/Cover" ], "xbrltype": "domainItemType" }, "aimd_WeightedAverageNumberOfSharesUsedInComputingNetLossPerShareAttributableToCommonStockholdersBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted-average number of shares used in computing net loss per share attributable to common stockholders, basic and diluted" } } }, "localname": "WeightedAverageNumberOfSharesUsedInComputingNetLossPerShareAttributableToCommonStockholdersBasicAndDiluted", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "aimd_WeightedAverageNumberOfSharesWarrantsToPurchaseCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants to purchase common stock", "verboseLabel": "Warrants to purchase common stock" } } }, "localname": "WeightedAverageNumberOfSharesWarrantsToPurchaseCommonStock", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/NetLossPerCommonShareDetails1", "http://aimd.com/role/SharebasedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "aimd_WeightedAverageSharesOutstandingConvertibleNotePurchaseCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible note to purchase common stock" } } }, "localname": "WeightedAverageSharesOutstandingConvertibleNotePurchaseCommonStock", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/NetLossPerCommonShareDetails1" ], "xbrltype": "sharesItemType" }, "aimd_totaling": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Totaling" } } }, "localname": "totaling", "nsuri": "http://aimd.com/20230630", "presentation": [ "http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aimd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aimd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aimd.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aimd.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aimd.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aimd.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aimd.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aimd.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aimd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aimd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aimd.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aimd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line 2" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aimd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aimd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aimd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aimd.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aimd.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aimd.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aimd.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aimd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aimd.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aimd.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aimd.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aimd.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aimd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aimd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aimd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aimd.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aimd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aimd.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aimd.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aimd.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsReceivableNet": { "auth_ref": [ "r317", "r325" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "[Accounts Receivable, after Allowance for Credit Loss]", "verboseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r173", "r174" ], "calculation": { "http://aimd.com/role/CondensedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable (including amounts of related party of nil and $177,595 as of June 30, 2023 and December 31,2022, respectively)" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDeferredInvestmentTaxCredit": { "auth_ref": [ "r18", "r47", "r391" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The noncurrent portion of the reserve for accumulated deferred investment tax credits as of the balance sheet date. This is the remaining investment credit, which will reduce the cost of services collected from ratepayers by a ratable portion over the investment's regulatory life.", "label": "Unpaid accrued interest" } } }, "localname": "AccumulatedDeferredInvestmentTaxCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r23", "r25", "r69", "r287", "r320", "r321", "r349", "r350", "r351", "r355", "r356", "r357" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r8", "r336" ], "calculation": { "http://aimd.com/role/CondensedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r249", "r250", "r251", "r355", "r356", "r357", "r393" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Total potential shares" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/NetLossPerCommonShareDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r79", "r86", "r104", "r128", "r161", "r164", "r168", "r175", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r267", "r271", "r276", "r336", "r362", "r363", "r398" ], "calculation": { "http://aimd.com/role/CondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets]", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r100", "r109", "r128", "r175", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r267", "r271", "r276", "r336", "r362", "r363", "r398" ], "calculation": { "http://aimd.com/role/CondensedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets, Current]", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389" ], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date Axis" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetails", "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [ "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389" ], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetails", "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/SharebasedCompensationDetails", "http://aimd.com/role/SharebasedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r0", "r46", "r53" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "verboseLabel": "Description of Business" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/DescriptionOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r40", "r102", "r328" ], "calculation": { "http://aimd.com/role/CondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "verboseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CashAndCashEquivalents" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r35", "r40", "r45" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents]", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r35", "r76" ], "calculation": { "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect]", "totalLabel": "Net (decrease) increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash financing and investing activities" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r105", "r106", "r107", "r128", "r144", "r145", "r147", "r148", "r151", "r152", "r175", "r180", "r182", "r183", "r184", "r187", "r188", "r202", "r203", "r205", "r209", "r215", "r276", "r327", "r343", "r353", "r358" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/Cover", "http://aimd.com/role/SharebasedCompensationDetailsNarrative", "http://aimd.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r63", "r65" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class Of Warrant Or Right Axis" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "[Class of Warrant or Right, Outstanding]", "verboseLabel": "Total" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r58", "r178", "r179", "r326", "r361" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Issuance of common shares, vested" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/SharebasedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockOtherSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.", "label": "Common stock issued and outstanding" } } }, "localname": "CommonStockOtherSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued (in shares)", "verboseLabel": "Common stock" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedBalanceSheetsParenthetical", "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r7", "r61" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r7", "r336" ], "calculation": { "http://aimd.com/role/CondensedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.01 par value; 300,000,000 shares authorized as of June 30, 2023 and December 31, 2022, 20,292,624 and 20,011,602 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r26", "r111", "r113", "r119", "r314", "r318" ], "calculation": { "http://aimd.com/role/CondensedStatementsOfComprehensiveLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "[Comprehensive Income (Loss), Net of Tax, Attributable to Parent]", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockDescription": { "auth_ref": [ "r42", "r43", "r44" ], "lang": { "en-us": { "role": { "documentation": "A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Stock split description", "verboseLabel": "Conversion price description" } } }, "localname": "ConversionOfStockDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetailsNarrative", "http://aimd.com/role/DescriptionOfBusinessDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r42", "r43", "r44" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of stock", "verboseLabel": "Issuance of common stock" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative", "http://aimd.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertibleNotesPayable": { "auth_ref": [ "r4", "r80", "r87", "r94" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.", "label": "Total Convertible and other notes payable", "terseLabel": "Convertible notes payable", "verboseLabel": "Total Convertible and other notes payable" } } }, "localname": "ConvertibleNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetails", "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetailsNarrative", "http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableCurrent": { "auth_ref": [ "r14" ], "calculation": { "http://aimd.com/role/CondensedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible notes payable, related party" } } }, "localname": "ConvertibleNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r30", "r128", "r175", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r276", "r362" ], "calculation": { "http://aimd.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 3.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "[Cost of Revenue]", "negatedLabel": "Cost of revenues" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r42", "r44" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Additional stock issued" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionOriginalDebtAmount1": { "auth_ref": [ "r42", "r44" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Purchase of equipment and intangible assets by issuing convertible notes payable to a related party" } } }, "localname": "DebtConversionOriginalDebtAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r60", "r126", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "verboseLabel": "Convertible Notes Payable and Other Notes Payable" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r59", "r190" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Conversion price" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r16", "r189" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DeferredRevenueDisclosureTextBlock": { "auth_ref": [ "r96" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for deferred revenues at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.", "label": "Deferred Revenue Disclosure [Text Block]", "verboseLabel": "Revenue" } } }, "localname": "DeferredRevenueDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_DepositsAssets": { "auth_ref": [ "r344" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.", "label": "Deposits from related party" } } }, "localname": "DepositsAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r38", "r56" ], "calculation": { "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DescriptionOfInterestRateDerivativeActivities": { "auth_ref": [ "r70", "r71", "r72", "r73", "r74", "r75" ], "lang": { "en-us": { "role": { "documentation": "General discussion of the entity's interest rate derivative activities.", "label": "Interest rate description" } } }, "localname": "DescriptionOfInterestRateDerivativeActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r218", "r245", "r246", "r248", "r252", "r333" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/SharebasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r395" ], "calculation": { "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 21.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect from foreign currency exchange" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Unrecognized Option Expense Period Of Recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/SharebasedCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r390" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Unrecognized Option Expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/SharebasedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOwnershipPlanESOPSharesInESOP": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "Sum of the allocated, committed-to-be-released and suspense shares of the entity held by the plan.", "label": "Number Of Shares Of Common Stock Issued" } } }, "localname": "EmployeeStockOwnershipPlanESOPSharesInESOP", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/SharebasedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r61", "r98", "r114", "r115", "r116", "r131", "r132", "r133", "r135", "r140", "r142", "r150", "r176", "r216", "r249", "r250", "r251", "r257", "r258", "r274", "r278", "r279", "r280", "r281", "r282", "r284", "r287", "r320", "r321", "r322" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_FlightEquipmentNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net amount of long-lived, depreciable flight assets used in the entity's principle business operations, including owned aircraft and on capital lease, as well as capitalized improvements.", "label": "Equipment" } } }, "localname": "FlightEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r29", "r128", "r161", "r163", "r167", "r169", "r175", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r276", "r332", "r362" ], "calculation": { "http://aimd.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 7.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "[Gross Profit]", "totalLabel": "Gross (loss) profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r27", "r78", "r82", "r93", "r161", "r163", "r167", "r169", "r315", "r332" ], "calculation": { "http://aimd.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Net loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Statements of Operations (Unaudited)" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r129", "r254", "r255", "r256", "r259", "r261", "r263", "r264", "r265" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": { "auth_ref": [ "r392" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.", "label": "Unpaid accrued interest expenses" } } }, "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r130", "r141", "r142", "r160", "r253", "r260", "r262", "r319" ], "calculation": { "http://aimd.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r37" ], "calculation": { "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "[Increase (Decrease) in Accounts Receivable]", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r37" ], "calculation": { "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "[Increase (Decrease) in Inventories]", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r352" ], "calculation": { "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "[Increase (Decrease) in Other Current Assets]", "negatedLabel": "Other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "auth_ref": [ "r352" ], "calculation": { "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current liabilities classified as other.", "label": "Accrued expenses and other current and long-term liabilities" } } }, "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPayablesToCustomers": { "auth_ref": [ "r352" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The change during the period, either increase or decrease, in amounts payable to customers. The term customers generally excludes other broker-dealers; persons who are principal officers, directors, and stockholders; and persons whose securities or funds are part of the regulatory net capital of the broker-dealer. Another broker-dealer's account can be classified as a customer if the account is carried as an omnibus account in compliance with certain regulations. The accounts of principal officers, directors and stockholders may be combined in the customer captions if they are not material and the combination is disclosed in the oath that is required to accompany the annual audited FOCUS Report.", "label": "Payable for purchase of equipment" } } }, "localname": "IncreaseDecreaseInPayablesToCustomers", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r55", "r297", "r298", "r299", "r301", "r330" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "Impairment of Intangible Assets" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r77", "r85", "r117", "r159", "r286" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "[Interest Expense]", "verboseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseTradingLiabilities": { "auth_ref": [ "r84" ], "calculation": { "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest expense incurred on short positions arising from sales of securities and other assets, which the entity does not own, to other parties. Trading liabilities includes the fair value of derivative contracts held for trading that are in loss positions.", "label": "Contract liabilities" } } }, "localname": "InterestExpenseTradingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://aimd.com/role/CondensedStatementsOfOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "[Interest Income (Expense), Nonoperating, Net]", "totalLabel": "Total non-operating expenses, net" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r120", "r123", "r124" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRevenueExpenseNet": { "auth_ref": [ "r161" ], "calculation": { "http://aimd.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 8.0, "parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest revenue (income derived from investments in debt securities and on cash and cash equivalents) net of interest expense (cost of borrowed funds accounted for as interest).", "label": "Interest expense" } } }, "localname": "InterestRevenueExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r345" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r108", "r329", "r336" ], "calculation": { "http://aimd.com/role/CondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, net", "verboseLabel": "Total" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedBalanceSheets", "http://aimd.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r347" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r346" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Work in process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r177" ], "calculation": { "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Loss on inventory write-downs" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r13", "r128", "r175", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r268", "r271", "r272", "r276", "r331", "r362", "r398", "r399" ], "calculation": { "http://aimd.com/role/CondensedBalanceSheets": { "order": 20.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "[Liabilities]", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r12", "r81", "r90", "r336", "r354", "r360", "r394" ], "calculation": { "http://aimd.com/role/CondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "[Liabilities and Equity]", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r15", "r101", "r128", "r175", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r268", "r271", "r272", "r276", "r336", "r362", "r398", "r399" ], "calculation": { "http://aimd.com/role/CondensedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "[Liabilities, Current]", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r1", "r2", "r3", "r4", "r5", "r128", "r175", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r268", "r271", "r272", "r276", "r362", "r398", "r399" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Long term liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesSubjectToCompromiseDebtAndAccruedInterest": { "auth_ref": [ "r397" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of debt and related accrued interest included in liabilities subject to compromise.", "label": "Accrued interest and the remaining principal amount" } } }, "localname": "LiabilitiesSubjectToCompromiseDebtAndAccruedInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketDataRevenue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue from market data services, including, but not limited to, information about current quotes and most recent prices for a specific security.", "label": "Market price" } } }, "localname": "MarketDataRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r122" ], "calculation": { "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 20.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "[Net Cash Provided by (Used in) Financing Activities]", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r122" ], "calculation": { "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 19.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "[Net Cash Provided by (Used in) Investing Activities]", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r35", "r36", "r39" ], "calculation": { "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 18.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "[Net Cash Provided by (Used in) Operating Activities]", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r28", "r39", "r83", "r92", "r99", "r110", "r112", "r116", "r128", "r134", "r136", "r137", "r138", "r139", "r141", "r142", "r146", "r161", "r163", "r167", "r169", "r175", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r275", "r276", "r332", "r362" ], "calculation": { "http://aimd.com/role/CondensedStatementsOfComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://aimd.com/role/CondensedStatementsOfOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "[Net Income (Loss) Attributable to Parent]", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfComprehensiveLossUnaudited", "http://aimd.com/role/CondensedStatementsOfOperationsUnaudited", "http://aimd.com/role/CondensedStatementsOfStockholdersEquityUnaudited", "http://aimd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements Adopted" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-operating income (expenses), net:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r4", "r80", "r88" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://aimd.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 6.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "[Operating Expenses]", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r161", "r163", "r167", "r169", "r332" ], "calculation": { "http://aimd.com/role/CondensedStatementsOfOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "[Operating Income (Loss)]", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r14" ], "calculation": { "http://aimd.com/role/CondensedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Accrued expenses and others current liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAdditionalCapital": { "auth_ref": [ "r21", "r32" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of additional paid-in capital (APIC) classified as other.", "label": "Working capital" } } }, "localname": "OtherAdditionalCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r103" ], "calculation": { "http://aimd.com/role/CondensedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": { "auth_ref": [ "r22", "r24", "r277", "r283" ], "calculation": { "http://aimd.com/role/CondensedStatementsOfComprehensiveLossUnaudited": { "order": 3.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "[Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax]", "negatedLabel": "Translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r17" ], "calculation": { "http://aimd.com/role/CondensedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNotesPayableCurrent": { "auth_ref": [ "r14" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Other notes payable, related party - current" } } }, "localname": "OtherNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingIncomeExpenseNet": { "auth_ref": [], "calculation": { "http://aimd.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 9.0, "parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.", "label": "Other income, net" } } }, "localname": "OtherOperatingIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r6", "r202" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r6", "r202" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, par value (in dollars per share)B2" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r348" ], "calculation": { "http://aimd.com/role/CondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r33" ], "calculation": { "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from convertible notes payable, related party" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r33" ], "calculation": { "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from convertible notes payable" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r33" ], "calculation": { "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from other notes payable, related party" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r99", "r110", "r112", "r121", "r128", "r134", "r141", "r142", "r161", "r163", "r167", "r169", "r175", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r266", "r269", "r270", "r275", "r276", "r315", "r332", "r334", "r335", "r351", "r362" ], "calculation": { "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "[Net Income (Loss), Including Portion Attributable to Noncontrolling Interest]", "negatedLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAdditions": { "auth_ref": [], "calculation": { "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Purchase of property and equipment" } } }, "localname": "PropertyPlantAndEquipmentAdditions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r57", "r91", "r316", "r336" ], "calculation": { "http://aimd.com/role/CondensedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r217", "r290", "r291" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetailsNarrative", "http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r97", "r290", "r291", "r396" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction Axis" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r97" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r217", "r290", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r396" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party Transactions By Related Party Axis" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetailsNarrative", "http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r288", "r289", "r291", "r292", "r293" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "verboseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfConvertibleDebt": { "auth_ref": [ "r34" ], "calculation": { "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "[Repayments of Convertible Debt]", "negatedLabel": "Repayments of convertible notes payable, related party" } } }, "localname": "RepaymentsOfConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations": { "auth_ref": [], "calculation": { "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for short-term and long-term debt and lease obligation.", "label": "[Repayments of Debt and Lease Obligation]", "negatedLabel": "Operating lease liabilities" } } }, "localname": "RepaymentsOfDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r34" ], "calculation": { "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "[Repayments of Notes Payable]", "negatedLabel": "Repayments of other notes payable, related party" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r68", "r95", "r400" ], "calculation": { "http://aimd.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development expenses", "verboseLabel": "Development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfOperationsUnaudited", "http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r40", "r45", "r102" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Restricted Cash and Cash Equivalents, Current]", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/SharebasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r9", "r62", "r89", "r323", "r324", "r336" ], "calculation": { "http://aimd.com/role/CondensedBalanceSheets": { "order": 18.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit", "verboseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedBalanceSheets", "http://aimd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r98", "r131", "r132", "r133", "r135", "r140", "r142", "r176", "r249", "r250", "r251", "r257", "r258", "r274", "r320", "r322" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r118", "r128", "r157", "r158", "r162", "r165", "r166", "r170", "r171", "r172", "r175", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r276", "r315", "r362" ], "calculation": { "http://aimd.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of basic and diluted net loss per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/NetLossPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).", "label": "Schedule of computations of diluted weighted average shares outstanding" } } }, "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/NetLossPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r31" ], "calculation": { "http://aimd.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r37" ], "calculation": { "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based compensation", "terseLabel": "Share-based compensation expense", "verboseLabel": "Share-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited", "http://aimd.com/role/CondensedStatementsOfStockholdersEquityUnaudited", "http://aimd.com/role/SharebasedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ShareBased Compensation" } } }, "localname": "ShareBasedCompensationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "RSUs granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/SharebasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Weighted-Average Grant Date Fair Value Per RSUs granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/SharebasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/SharebasedCompensationDetails", "http://aimd.com/role/SharebasedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Public offering price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/DescriptionOfBusinessDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares]", "periodEndLabel": "Options outstanding, Ending", "periodStartLabel": "Options Outstanding, Beginning" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/SharebasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options forfeited.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares]", "negatedLabel": "RSUs forfeited" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/SharebasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options forfeited.", "label": "Weighted-Average Grant Date Fair Value Per RSUs forfeited" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/SharebasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options outstanding.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price]", "periodEndLabel": "Weighted-Average Grant Date Fair Value Per RSU, ending balance", "periodStartLabel": "Weighted-Average Grant Date Fair Value Per RSU, beginning balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/SharebasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares]", "negatedLabel": "RSUs vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/SharebasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Weighted-Average Grant Date Fair Value Per RSUs vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/SharebasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "[Shares, Issued]", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r46", "r125" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "verboseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r105", "r106", "r107", "r128", "r144", "r145", "r147", "r148", "r151", "r152", "r175", "r180", "r182", "r183", "r184", "r187", "r188", "r202", "r203", "r205", "r209", "r215", "r276", "r327", "r343", "r353", "r358" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/Cover", "http://aimd.com/role/SharebasedCompensationDetailsNarrative", "http://aimd.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r20", "r61", "r98", "r114", "r115", "r116", "r131", "r132", "r133", "r135", "r140", "r142", "r150", "r176", "r216", "r249", "r250", "r251", "r257", "r258", "r274", "r278", "r279", "r280", "r281", "r282", "r284", "r287", "r320", "r321", "r322" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfStockholdersEquityUnaudited", "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetails", "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetailsNarrative", "http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative", "http://aimd.com/role/SharebasedCompensationDetails", "http://aimd.com/role/SharebasedCompensationDetailsNarrative", "http://aimd.com/role/StockholdersEquityDetails", "http://aimd.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Statements of Cash Flows (Unaudited)" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Balance Sheets" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Statements of Comprehensive Loss (Unaudited)" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Statements of Stockholders Equity (Unaudited)" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r131", "r132", "r133", "r150", "r300" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfStockholdersEquityUnaudited", "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetails", "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetailsNarrative", "http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative", "http://aimd.com/role/SharebasedCompensationDetails", "http://aimd.com/role/SharebasedCompensationDetailsNarrative", "http://aimd.com/role/StockholdersEquityDetails", "http://aimd.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r6", "r7", "r62", "r66" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Issuance of common stock in exchange of vehicle" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r7", "r10", "r11", "r54", "r336", "r354", "r360", "r394" ], "calculation": { "http://aimd.com/role/CondensedBalanceSheets": { "order": 21.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "[Stockholders' Equity Attributable to Parent]", "periodEndLabel": "Balance, amount", "periodStartLabel": "Balance, amount", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedBalanceSheets", "http://aimd.com/role/CondensedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r64", "r127", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r216", "r273" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r285", "r295" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r285", "r295" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r285", "r295" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/ConvertibleNotesPayableAndOtherNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r294", "r296" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "verboseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r50", "r51", "r52", "r153", "r154", "r155", "r156" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r143", "r148" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted-average shares used in computing net loss per common share-basic and diluted" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesRestrictedStock": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends.", "label": "Option and RSUs to purchase common stock", "verboseLabel": "Option and RSUs to purchase common stock" } } }, "localname": "WeightedAverageNumberOfSharesRestrictedStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aimd.com/role/NetLossPerCommonShareDetails1", "http://aimd.com/role/SharebasedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.26(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30755-110894", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(b)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.T)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868742-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942793&loc=d3e3073-115593", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r337": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r338": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r339": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r341": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r342": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r361": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32262-109318", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=d3e56015-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r46": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "255", "URI": "https://asc.fasb.org/extlink&oid=125523840&loc=d3e2408-110839", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2646-109256", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.7)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "430", "URI": "https://asc.fasb.org/topic&trid=2122452", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 58 0001654954-23-010601-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001654954-23-010601-xbrl.zip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

	1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

	AINOS, INC.

Date: August 11, 2023	By:	/s/ Meng-Lin Sung
		Meng-Lin Sung, Principal Financial Officer (Chief Financial Officer)